University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2020

Modulation of inflammatory pathway by inflammatory inhibitor
JSH-23 mitigates diabetic retinopathy.
Rubens Petit Homme
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Endocrine System Diseases Commons, Eye Diseases Commons, and the Immune System
Diseases Commons

Recommended Citation
Petit Homme, Rubens, "Modulation of inflammatory pathway by inflammatory inhibitor JSH-23 mitigates
diabetic retinopathy." (2020). Electronic Theses and Dissertations. Paper 3479.
https://doi.org/10.18297/etd/3479

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

MODULATION OF INFLAMMATORY PATHWAY BY INFLAMMATORY INHIBITOR
JSH-23 MITIGATES DIABETIC RETINOPATHY

By
Rubens Petit Homme
B.S., Florida Southern College, 2016
M.S., University of Louisville, 2019

A Dissertation
Submitted to the University of Louisville School of Medicine
In Partial Fulfillment of the Requirements
for the Degree of

Doctor of Philosophy
in Physiology and Biophysics

Department of Physiology
University of Louisville
Louisville, Kentucky

August 2020

MODULATION OF INFLAMMATORY PATHWAY BY INFLAMMATORY
INHIBITOR JSH-23 MITIGATES DIABETIC RETINOPATHY

By
Rubens Petit Homme
B.S., Florida Southern College, 2008
M.S., University of Louisville, 2019

A Dissertation Approved on

May 18, 2020

By the following Dissertation Committee
________________________________
Suresh C. Tyagi, Ph.D., Mentor
________________________________
Mahavir Singh, Ph.D., Co-Mentor
________________________________
Irving G. Joshua, Ph.D.
________________________________
Neetu Tyagi, Ph.D.
________________________________
Sandhu Harpal, M.D.

ii

DEDICATION

To my brothers Robens Manno & Ferry Petit Homme, Juan Luis Garcia, my sisters
Brindy, Luchandley, Guerlie, and Rose
My Parents, Mrs. Elicienne and Mr. Bienera Petit Homme,
My best men & women, Tervens, Clay, Senatus, Anne, & Frederick
The moms and dads that showed me my left foot from my right, aunt Clarine,
Guerda, Ginette, Roseline, Mrs. Honors, Ms. Evon, Grandma Dada, Dr. Gauthier,
Dr. Lee, Dr. Eubank, Dr. Crowe, Mr. Ferdinand, Coach Locke, and of course Dr.
Adrienne Bratcher
To my city, La Pointe Des Palmistes,
My guardian angels, Terancia, Aunt Paulna, & Mrs. Serafin,
My Church, First Baptist Church of Nazarene in Lakeland,
My alma matter, the Red Devils and the Moccasins
To those that want but never was as privileged as I am “Habacuc Milord.”
To my family that has walked, continue to walk, and will always walk with me through
all the paths of my life.
It’s a great remorse that all your names cannot fit within one page.
All the cells and water in my body would like to say, “Thank you for sharing the love
with me all the days of my life!”
My people continue to share the love, and I’m the living proof that your grace has no
limit to the success it can bring to someone.

iii

ACKNOWLEDGEMENTS
I am truly blessed and privileged to have the opportunity to conduct my research
with the best and the brightest people in the best University under the sky. It is with great
pleasure that I would like to thank my mentor and my best soccer-mate, Dr. Suresh C.
Tyagi for his support, encouragement, and guidance, for the past four years in his
laboratory. His leadership and love for the scientific endeavors are incomparable. I would
like to thank him not only for teaching me the know-how in the laboratory but also for
sharing a soccer field with me. Soccer has been the remedy for my life, particularly under
challenging days; it was a treasure to share the pitch with my mentor. As people say it is
always better with a little humor; Dr. Mahavir Singh never ceases to amaze me with his
sense of humor. He was there to support and guide me when things were well or not well
in the lab. I am tremendously grateful for his mentorship. I would like to thank Dr.
Joshua not only for his advice and guidance about my research but also for teaching me
about the strategic career planning, something that I used not only for myself but also for
my organization (BASSA). Further, I would like to thank Dr. Neetu Tyagi for serving on
my committee, for her advice, support, and kindness over the years.
Additionally, I would also like to thank Dr. Sandhu for serving on my
committee, arranging clinical samples, increasing my clinical knowledge on Diabetic
Retinopathy, and encouragement over the years. I would also like to thank Dr. Bratcher
who has always been there with me since my very first day in Louisville, mentored me as
her from a summer student with the Summer Cardiovascular Research Programs to the
Ph.D. application, qualification, and hopefully soon graduation. I would like to take this
time to
iv

salute all the professors of the Department of Physiology for their guidance and
knowledge during the last four years. I would also like to offer my utmost gratitude to
Denise, Jennifer, and Carol for their constant love, support, help, and assistance for the
last four years.

I would like to thank all our lab members for creating a supportive and inclusive
work environment and years of friendship. Salute to Naira Metreveli, Irina Smolenkova,
Anwesha Laha, Dr. Akash K. George, Dr. Papujohn, Dr. Thielen, and Dr. Majumder for their
assistance, advice, teaching, and love during my studies.

v

ABSTRACT

MODULATION OF INFLAMMATORY PATHWAY BY INFLAMMATORY
INHIBITOR (JSH-23) MITIGATES DIABETIC RETINOPATHY

Rubens Petit Homme

August 11, 2020

Diabetic retinopathy (DR) is the most common microvascular complication of
diabetes mellitus (DM). Its pathology is consisted of the breakdown of the blood-retinal
barrier (BRB), particularly the inner blood-retinal barrier (iBRB). The exact mechanism
that leads to the iBRB impairment and the development of DR has not been elucidated
yet. However, chronic inflammation that is hallmark of the type I DM has recently
become a key focus in DR study. Hyperglycemia causes dysregulation of nuclear factorkappa B (NF-); and its constant activation increases the expression of inducible nitric
oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and intercellular adhesion
molecule-1 (ICAM-1) in the retina and vitreous of DR patients and animal models. This
increase in inflammatory mediators leads to the degradation of junctional molecules,
occludin, connexin-43, death of retinal cells via pyroptosis, and thus disruption of the
iBRB. Derailment of the iBRB induces fluid accumulation into the retina of DR
patients, which eventually progresses into vision impairment. The purpose of this study
vi

is to investigate whether chronic inflammation in DM induces disruption of iBRB; and
whether inhibition of the expression and activity of NF- by Methyl-N1-(3-phenyl
propyl) benzene-1, 2-diamine (JSH-23) would mitigate this iBRB disruption.

Methods: Type 1 diabetic mouse model (Akita) on a C57BL/6J background along with
non-diabetic littermate were used in the experiments. All mice were 22-24 weeks of age
at the start of the experiments. The experimental and the control animals were treated for
four weeks on alternate days with JSH-23 @5mg/Kg body weight. The intraocular
pressure (IOP), blood pressure, blood glucose, and body weights of all animals were
measured before and after treatment. Fluorescence angiography (FA), optical coherence
tomography (OCT), and dark-adapted electroretinogram were performed before and after
the treatment. Also, intraperitoneal glucose tolerance test (GTT) were performed in the
animals before and after the treatment. Then, the retinas and plasma were collected.
Western blotting and real-time polymerase chain reaction were performed to analyze
protein expression and the mRNA levels of NF- p65, iNOS, COX-2, ICAM-1,
occludin, connexin-43, NLRP3, caspase-1, and IL-1. Additionally, plasma insulin levels
were also analyzed via ELISA kit.

Results: The body weight of Akita mice was significantly lower than the C57BL/6J
mice. The treatment with JSH-23 did not have any effect on body weight. The blood
glucose of Akita mice was significantly higher than the blood glucose of non-diabetic
littermate control mice. The treatment substantially decreased blood glucose in Akita
mice. Also, the plasma insulin level for the Akita mice was significantly lower
vii

compared to non-diabetic littermate control mice. The intraperitoneal
GTT showed that the Akita mice were unable to lower their blood glucose levels.
The total and phosphorylated protein expression levels of NF-B p65 were significantly
decreased after treatment with JSH-23 in Akita mice, and the gene expression of NF-B
p65 also reduced. The protein and gene expression levels of iNOS, COX-2, and ICAM-1
were reduced after treatment in Akita mice, and the treatment significantly lowered the
expression of pyroptosis marker NLRP3. The gene expression of other proteins in the
pyroptosis pathway were also reduced, including caspase-1 and IL-1. On the other hand,
the protein and gene expression levels of junctional molecules occludin, connexin-43
were significantly increased in Akita mice after treatment with JSH-23.
The blood pressure of the animals was normal and the treatment did not have any effect
on the blood pressure. FA depicted an increase in retinal capillary permeability in Akita
mice, and the treatment significantly reduced that permeability. The OCT showed retinal
layers thickening in the retina of Akita mice, and treatment increased the retinal layers
thickness. Electroretinogram (ERG) showed an increase in the amplitude of the A-wave
and the B-wave in Akita mice.

Conclusions: The results showed that inhibitor (JSH-23) improved visual function by
decreasing the retinal vascular permeability, IOP, and the retinal inflammation in Akita
mice.
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CHAPTER I
GENERAL INTRODUCTION

Retina
Phototransduction carried out by retinal neuronal cells, supported by retinal glial
cells (RGC), is the primary function of the retina [1-4]. Phototransduction is divided into
three parts: a receptor (rhodopsin), G-protein (transducin), and an effector (cGMP
phosphodiesterase or PDE/PDE6). It starts with 11-cis retinal absorption of a photon that
leads to a conformational change in 11-cis retinal to 11-trans retinal. Rhodopsin is
activated (metarhodopsin II), which then enables transducin [3, 5].
Transducin activate cGMP phosphodiesterase (PDE). PDE, hydrolyze cGMP,
lead to the closing of a cGMP-gated ion channel in the membrane. PDE decreases cGMP
concentration; as a result, the cGMP-dependent gated channels in the plasma membrane
closed. Uptake of cation reduces in the photoreceptor outer segment (POS); the
membrane hyperpolarizes. That decreases the secretion of glutamate. Termination of
phototransduction involves inactivation of rhodopsin, transducin, PDE, and increasing
concentration of cGMP. Rhodopsin kinase (GRK1) phosphorylated rhodopsin; protein
arrestin (Arr1) complete the inactivation by binding to the receptor [6, 7]. G-PDE
inactivated by RGS9-1- G-protein signaling protein [8]; Guanylyl cyclase restored the
concentration of cGMP [9, 10].
The vision cycle is divided into dark and light periods. The dark period leads to a
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constant flow of Na+ into the photoreceptor, thus depolarizing the plasma membrane.
Depolarization triggers the release of glutamate however during the light cycle, the
opposite happens, the flow of Na+ stops, and thus the plasma membrane hyperpolarizes
and the glutamate secretion stops [11-13].
Rods photoreceptors are sensitive to blue-green light (peak ~ 500 nm
wavelengths). In fact, they are very sensitive and at the same time highly efficient in
capturing a single photon [14]. Visual pigments in cones are the opsin molecules, and
cones sensitivity depends on the molecular structure of opsin for the long wavelengths
(red light), short-wavelength (blue light), and medium wavelength (green light).

Anatomy and Physiology of the Retina
The retina is a semi-circle with a diameter between 30 and 40 mm, 0.5 mm
thickness, lining the posterior part of the eye. All the major blood vessels of the retina
converge towards the center to form the optic nerve. The foveal (the center of the macula)
contains no blood vessels and only cone photoreceptors are located to the left of the optic
nerve. The retina is divided into two areas: the central (macula) and the peripheral retina.
The central retina is the circular area with a 6 mm diameter from the fovea, while the
peripheral retina is everything outside of the central retina [15].
The retina is further divided into ten different layers of cells and cell bodies such
as outer nuclear layer (ONL), inner nuclear layer (INL), inner plexiform layer (IPL),
outer plexiform layer (OPL), ganglion cell layer (GCL), outer limiting membrane
(OLM), nerve fiber layers (NFL), inner limiting membrane (ILM), and the retinal
pigment epithelium (RPE). The cell layers contain ganglion, photoreceptors, and
epithelial cells. The ganglion cells (GCs) are closest to the retina and serves as the output
of photoreceptors and input to the optic nerve. The photoreceptors capture and transduce
2

light, while the epithelial performs many functions to maintain retinal homeostasis.
The cell bodies of first-order neurons (rods and cones photoreceptors) reside in
the ONL. The INL houses the cell bodies of second-order neurons (bipolar, horizontal,
and amacrine cells). First-order and second-order neurons synapse in the OPL. GCs and
second-order neurons synapse in the IPL. The OLM contains adherens junctions between
photoreceptors and Müller cells, while the ILM houses the Müller cells. The OLM forms
a barrier between the outer retina and the subretinal space, while the ILM forms a barrier
between the inner retina and the vitreous humor. All retinal cell layers are perfused
mainly by the central retinal artery (CRA).
The retina has two main blood supplies: choroid (perfused photoreceptors)
responsible for about ¾ of retinal blood supply, and the CRA (perfused inner retina),
responsible for the last ¼ of the retinal blood supply [16]. The retinal layers are perfused
via retinal capillaries. The retinal capillaries form a network throughout the retina, radial
peripapillary capillaries (RPCs), inner and outer layer capillaries. The RPCs is located
within the NFL and is alimented about 5 mm from the optic disc, inner capillaries
alimented the GCL, while the outer capillary aliments the IPL, OPL, and the INL [16,
17].

Outer Plexiform Layer (OPL). Second-order neurons synapses with photoreceptors in the
OPL to propagate the signals. The OPL contains mainly two types of cells: bipolar and
horizontal cells. The retina contains 11 different types of bipolar cells, all except one
synapse with cones photoreceptors [18-21]. Bipolar cell bodies reside in the INL, with
dendrites located in the OPL. Some photoreceptors synapse with one bipolar cell while
other with many bipolar cells. There are also some bipolar cells that are photoreceptors
specific, e.g., S-cone. Bipolar cells designated as either ON or OFF [19]. Bipolar cells
3

responded differently to glutamate. Based on the receptor, it could lead to depolarization
or hyperpolarization of the plasma membrane. Depolarization indicates an ON-bipolar
cell, while hyperpolarization indicates an OFF-bipolar cell [22]. The ON-bipolar cell has
mGluR6 glutamate receptors [23, 24] while OFF-bipolar cell has iGluR AMPA-kainate
glutamate receptors [25]. The retina has only two distinct types of horizontal cells, which
are layered horizontally in the OPL [21]. In the presence of glutamate, horizontal cells
hyperpolarize. The IPL further carries the signal to amacrine and GCs.

Inner Plexiform Layer (IPL). Bipolar cells synapse with amacrine and GCs within the
IPL. There are various types of amacrine cells [19, 26]. They used serotonin,
acetylcholine, and other neurotransmitters for further transducing phototransduction
towards GCs [27-29]. They are various types of GCs as well [30, 31]. GCs are divided
into alpha, beta, gamma, and G4 to G23 [31]. Beta GCs are the most prevalent,
approximately half of all the GCs [32, 33]. The IPL separates the ON-bipolar and OFFbipolar cells by dividing the GCs into two compartments below the amacrine cells. The
ON-bipolar cells interact only with a compartment while the OFF-bipolar cells interact
with the other compartment [34-39]. The optic nerve synapses with the GCs and sends
the information to the brain.

Visual Responses of Ganglion Cells. Similar to bipolar cells, GCs are divided into ON,
OFF, and ON-OFF centers cells based on their response to light. ON-GCs fires a burst of
action potential (AP) upon stimulation then maintain the firing at a short interval. ONOFF-GCs fires AP when activated and then at the end of the stimulus, while OFF-GCs
centers fire AP at the end of the stimulus [40, 41]. OFF-GCs cells synapse with axon
terminal of OFF-bipolar cells in the proximity of the amacrine cell bodies, ON-GCs cells
4

synapses with ON-bipolar cells, while ON-OFF cells do both [36, 42]. As stated earlier,
GCs receive the final output of the signals, and they then send that output through the
brain via the optic nerve for interpretation. Another structure critical to retinal function is
the RPE.

Retinal Pigment Epithelium. The RPE located between the choroid and the POS. RPE
apical side faces the POS, while its basolateral side faces the Bruch’s Membrane. It has
pigments granules in a single sheet of cell shape that resembles a hexagon that links
together via tight junctions. The RPE contains organelles capable of digesting POS into
phagosomes. The RPE functions to absorb light, buffer ion, phagocytoses, epithelial
transport, secretion, and immune modulation.
Phototransduction results in a high amount of photo-oxidative energy within the
retina [63, 110]. The RPE located in the middle of the outer retinal blood flow (choroid)
[117]. The choroid perfuses substantially higher than the kidney [111, 112], while the
retina extraction of oxygen is significantly low, thus the choroidal venous blood is 90%
saturated with oxygen. RPE also phagocytoses POS. These factors increase the free
radicals levels in the RPE [63, 110]. RPE uses pigmented granules to defend itself from
the oxidative stress (OS) [113] that move to the apical side during light absorption [114,
115]. Aside from the pigmented granules, RPE uses antioxidants, and it has a high
capacity to repaired macromolecules such as lipids, DNA, and proteins that damaged due
to an increase of OS in the retina [113, 116].
The RPE separates the systemic and the subretinal flow, facilitates the transport
of nutrients to the retina, balances the ion in the retinal space, and removes metabolic
wastes from the retina. It also transports key phototransduction metabolites to the retina
such as glucose, retinal (retinaldehyde; a form of vitamin A), and -3 fatty acids.
5

Apical and basolateral glucose transporter 1 (inducible to meet metabolic needs)
and glucose transporter 3 facilitate glucose transport into the retina [118]. Retinal
transportation initiates with retinal uptake and then induces in the visual cycle—
absorption of 22:63 fatty are acids used to transport -3 fatty acid. The 22:63 fatty
acids are also used to synthesize glycerophospholipids for incorporation into the
membrane of photoreceptors [119].
The retina contains the highest cell density of any tissue in the human body and
its cells have a substantial metabolic turn-over, which increases the production of water
and thus its accumulation into the retina. Also, intraocular pressure (IOP) orient
movement of water towards the retina, further contributing to its accumulation into the
retina. There is also a substantial production of lactic acid in the retina (19 mM) due to
retinal metabolic activity [121]. RPE remove water via active transport through
aquaporin-1 located both in the apical and basolateral membrane of the RPE [122, 123].
The energy for that transport is obtained via the ubiquitous Na+/K+ pump located on the
apical front of the RPE which is located on the basolateral membrane. Lactic acid is
eliminated via mono-carboxylate transporter-1 (MCT1) (apical) and mono-carboxylate
transporter-3 (MCT3) (basolateral). The pH regulation is mandatory for facilitating the
transport. MCT1 and MCT3 use H+ for the transport and is regulated via apical Na+/H+exchanger and Na+/HCO3- (1:2) co-transporter and basolateral Cl/HCO3- exchanger [124].
Through the transport of ions across its epithelial junctions, the RPE regulates the balance
of ions in the subretinal space. Additionally, to maintain homeostasis, RPE needs to
compensate for the fast change in ions in the subretinal space [125].
K+ ions are the main ion concentration that must be in check. During the dark
cycle, photoreceptors channels on the POS uptake Na+. The influx is balanced via the
apical membrane of the membrane of the RPE by releasing K+ ions into the subretinal
6

space. During the light cycle, the cations channels are closed; thus, there is a decrease
in the outflow of K+ from the inner segment. Also, the Na+/K+-ATPase pump of the POS
takes up K+. All these events combine to decrease the K+ concentration in the subretinal
space. RPE K+ channels such as Kir7.1 in the apical membrane release K+ into the
subretinal space to maintain [K+] concentration [125, 126].
The RPE is responsible for the conversion of 11-trans to 11-cis retinal to
maintain proper visual conduction [129]. First, the trans-retinal is transported through the
POS from the intradiscal space via an ATP-driven flippase. Trans-retinal is converted to
N-retinylidinephosphatidylethanolamine by reacting with phosphatidylethanolamine.
Then retinol-dehydrogenase reduces trans-retinal to trans-retinol in the membrane. Transretinol move to the subretinal space and the interphotoreceptor retinoid-binding protein
(IRBP) carries the trans-retinol to the RPE. In the RPE, cellular retinol-binding protein
transfers the trans-retinol to a protein complex. This complex contains three enzymes that
mediate the conversion of trans-retinol to cis-retinal. Lecithin retinol transferase (LRAT)
adds an acyl to the retinol. RPE65 (RPE protein with 63 kDa) catalyzes the reisomerization of acyl-retinol. And the 11-cis-retinol dehydrogenase oxidizes retinol to
11-cis retinal.
Photo-transduction destroys the POS, which is then replenished by the RPE via
RPE shredding of the damaged part and phagocytosis [130]. This process is regulated by
the circadian rhythm. It is a daily process that occurrs early in the day and activated by
light [131]. The phagocytosis mechanism is regulated via three receptors: V5 integrin,
CD36, and receptor-tyrosine kinase c-mer (MerTK) [132]. The V5 integrin mediates
the binding of POS to the RPE, MerTK is phosphorylated via focal adhesion kinase
[133]. That leads to the production of inositol-1, 4, 5-triphosphate leading to an increase
7

in Ca2+ concentration inside the cells, and CD36, thus activating the phagocytosis. The
blood-ocular barrier is another factor that plays a crucial role in the homeostasis of the
retina.

8

Figure 1. Schematic of Retinal Layers. The retina function to transmit light from the
outside world to the brain via the photoreceptors and second-order neurons. The retina
contains many different layers of cells and synapses, each played a distinct role in
phototransduction. From the outer layer to the inner layers, OLM, RPE, ONL, OPL, INL,
IPL, GCL, NFL, and the ILM.

9

FIGURE 1
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Blood Ocular Barrier
The blood-ocular barrier (BOB) system is divided into two parts: blood-aqueous
and blood-retinal barriers. BOB restricts the passage of ions and other blood-borne
molecules from penetrating the retina through the aqueous humor and the vitreous [43].
Breakdown of the BOB allows molecules and other drugs to diffuse to the retina and
induce inflammation. Another factor that contributes to retinal homeostasis is the
downregulating immune environment (DIE) in the eye [44]. Degradation of the bloodretinal barrier (BRB) and loss of the DIE are hallmarks of retinal diseases [45]. The BOB
system, along with the DIE, is critical in downregulating excessive inflammatory
response and in maintaining the retinal homeostasis.
The BOB contributes to the eye being a privilege tissue; thus helping the eye
abstains from variations in systemic circulations. The BOB maintains an ideal
environment for the avascular tissues in the eye and regulates the diffusion of chemicals
into the retina. Because once the molecules pass the ocular barriers, there is nothing that
can prevent their dissemination to the retina [46]. The blood-aqueous barrier is formed by
the ciliary body non-pigmented epithelium, Schelemm’s canal endothelium, and the
endothelium of the Iridal capillaries [47]. Whereas, the BRB consists of tight junctions
that restricts the movement of molecules in and out of the retina.

Blood Retinal Barrier
Blood Retinal Barrier. BRB consists of the inner and outer BRB. The inner BRB (iBRB)
formed by tight junctions (e.g., Occludin) between the adjacent endothelial cells (ECs),
and this endothelial layer rests on a basal lamina that is covered by pericytes and glial
cells (astrocytes, and Müller cells) [48, 49]; whereas the outer BRB is maintained by tight
junctions between adjacent RPE cells [48, 50]. The BRB functions to control the
11

movement of molecules and fluid into the retina also prevents leakage of macromolecules
and harmful agents into the retina.

Endothelial Cells. The endothelial cells (ECs) provide the necessary nutrients and oxygen
the retina needs to maintain its physiological functions while limiting other blood
circulating agents from penetrating the retina. ECs mitigate transcellular and paracellular
transport into the retina. Transcellular transport occurs through diffusion across the lipid
bilayer for a host of small lipophilic molecules. The other mechanism of transportation is
through receptor-mediated or constitutive transcytosis. Caveolin-1 contains receptors for
many substances, including interleukin 1, vascular endothelial growth factor (VEGF),
albumin, advanced glycation end-products (AGES), and protein kinase C (PKC).
Vesicular transport under normal conditions is minimal [51]. Tight junctions restricted
the paracellular traffic.

Pericytes. In the formation of retinal vasculature, ECs express a very high level of
platelet-derived growth factor B (PDGF-B). It leads to the recruitment of pericyte cells,
which then wrap ECs in a 1:1 to ratio. They also form cell-cell contact via Cx43,
fibronectin adhesion plaques, and N-Cadherin. Pericytes also secrete angiopoietin-1
which acts via the Tie2 receptor on ECs to promote differentiation, remodeling, and
maturation. Pericytes also secrete Angiopoietin-2 (Ang-2) which moves together with
VEGF to promote angiogenesis. Overexpression of Ang-2 causes vascular regression,
impairs barrier function in part by inducing degradation of TJ (Cadherin). Pericytes also
secrete transforming growth factor-beta (TGF-) which inhibits migration and
proliferation of ECs [51].

12

Junctional Molecules
ECs form a restricted lining of the vascular wall to regulate the passage of
substances circulating in the blood and the interstitial space whereas, paracellular limit
transport via adhesive cell-cell junctional proteins that include gap junction (GP) and
tight-junction (TJ) [52].

Gap Junctions. GJ allowed cell-to-cell communication via hemichannels that are
consisted of six connexins molecules. Each cell contributes a hemichannel to the
connection, which opens the plasma membrane of each cell to the other. GJ allowed the
transfer of small molecules (< 1 kDa) such as ions, glucose, amino acids, and
neurotransmitters. Most cell types in the retina has GP, including photoreceptors [53],
endothelial, and pericytes [54]. Connexin-43 (Cx43) is the most prevalent connexin
molecule in the retina [55].

Cx43. Connexin generally localizes in the plasma membrane where it functions in
intercellular communications via GJ. Cx43 has various phosphorylation sites in its
carboxy-terminal for protein kinases, e.g., PKC. Cx43 is synthesized as a 40 to 42 kDa
protein which is then repeatedly phosphorylated through serine residues, and is
assembled in the trans-Golgi network, and then transported and inserted through the
plasma membrane. The phosphorylation usually functions in intercellular
communications via various molecular mechanisms related to assembly, trafficking, and
closing of the GJ channel [56, 57]. Cx43 hemichannels open during low [Ca2+]
extracellularly, while PKC can block its opening.

Tight Junctions: TJ are formed in proximity between two adjacent cells. TJ restrict
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transports of blood circulating molecules paracellularly. TJ also regulates lipid flip flop
across the lipid bilayer. They are consisted of more than 40 proteins that are generally
divided into transmembrane proteins and cytoplasmic scaffolding proteins [51].

Occludin: Occludin is a part of the transmembrane class of TJ proteins and is a 60 kDa
tetraspan transmembrane component protein with two loops facing the extracellular space
while both the amino and carboxy-termini in the cytoplasm. The amino terminus
regulates occludin degradation via interaction with E3-ubiquitin ligase; while the carboxy
terminus binds to one of the three Zona Occludentes proteins. Occludin functions more in
regulating barrier properties rather than structural properties between ECs.
Overexpression of occludin leads to decrease flux into the interstitial space.
Downregulation of occludin increases paracellular permeability. Occludin knockout mice
depicted that occludin is not required for barrier formation, but it does play a key role in
TJ trafficking and stabilization [51]. Occludin and claudins are the two protein/protein
family that link the ECs together [58].

Glia cells and the BRB
There are three different types of glial cells that populated the retina: Müller
cells, astrocytes, and microglia. The macroglial cells (Müller and astrocytes) play
significant roles by maintaining the function(s) of the iBRB.

Müller Cells. Müller cells are the primary macroglial cells in the retina and constitute
90% of the glial cells in the retina. Müller cells act as a linking cells for metabolites
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exchange between the neuronal cells and the blood vessels [59]. They function in
neurotransmitters recycling, K+ uptake, regulation of blood flow, metabolism control,
nutrients supply to retinal neurons, anti-oxidative support [60], glycogen storage [61],
sheath axons [59], and in maintaining the BRB. They can also interact closely with both
retinal neurons and blood vessels due to their long shape [62]. Docosahexaenoic (DHA)
protects photoreceptors disk membranes from oxidative damage. DHA also induces
increased expressions of anti-apoptotic factors via the Bcl-2 family. Müller cells function
in uptaking and delivering DHA to photoreceptors [59]. The depletion of Müller cells
leads to the breakdown of the BRB [61]. These cells secreted anti-angiogenic factors to
maintain pro and anti-angiogenic environment and thus BRB health.

Astrocytes. Astrocytes are non-prominent in avascularized area, generally located within
the NFL. They are wrapped around blood vessels. Astrocytes primarily communicates
via GJ [59]. Astrocytes are the primary producer of VEGF and thus play a key role in
neovascularization. Other physiological functions of astrocytes include mechanical
support for axons, neurotrophic support, and maintenance of the BRB. Astrocytes
contained aquaporin4 channels within their plasma membrane which help regulate the
fluid in the extracellular space, buffering potassium, and clear the metabolic wastes [59].
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Figure 2. A Brief Schematic of the iBRB. iBRB consists of TJ between adjacent ECs
that are covered by pericytes. The capillary cells are wrapped by glial cells (astrocytes,
and Müller cells). Although pericytes and glial cells are critical to the iBRB function, the
transcellular and paracellular transport into the retina is regulated by the ECs and TJ
together.
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Downregulatory Immune Environment (DIE). The immune-privileged status of the eye is
maintained by the BOB and DIE. Transportation of antigens and tissue drainage occurred
via the blood route instead of the lymphatic pathway [63]. The inflammatory response in
the eyes is particular to the eye. To protect the physiological functions, the eye regulates
immune response strictly and manages its inflammation. The retina and choroid contain
many immune cells that include choroidal macrophages, microglia, dendritic cells, and
the mast cells population [64]. These cells introduce antigen to T cells and produce
cytokines to non-specific stimuli such as bacterial liposaccharides (LPS). The presence of
antigen-non-specific inflammation can be disastrous to host tissue. The BRB protects the
retina from the aqueous chamber, and the vitreous body via immunosuppressive
functions. Many factors played a crucial roles in maintaining the DIE state in the eye,
including Müller cells, RPE, and the microglia. The normal retina has low major
histocompatibility complex (MHC) molecules and there is an absence of the bone
marrow-derived cells that function with tissues as Antigen Presenting Cells (APCs).

Anterior Chamber Associated Immune Deviation (ACAID). ACAID is the most studied
immune privilege mechanism in the eye. It is unique to the anterior chamber, but there is
evidence that the same mechanism exists in the vitreous and the subretinal space as well
[65]. It contains TGF- which is capable of reprogramming the APCs to produce less IL2, less amount of CD-40 in the microenvironment of the eye, and also help produce more
TGF- which suppresses T cell activation [46].

BRB and DR. DR is commonly defined as degeneration and occlusion of the
microvessels, which caused fluid accumulation and abnormal neovascularization in the
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retina [66]. Loss of pericytes in retinal capillaries is one of the factors that leads to iBRB
breakdown [67]. Hyperglycemia (HgA) causes retinal hypoxia and vasodilation increases
retinal blood flow in response to the hypoxia temporarily. Exhaustion of autoregulation
causes apoptosis of retinal capillary pericytes. The death of pericytes disrupts pericytesendothelial complex which then leads to an impairment in the endothelial TJ function.
These events together caused the breakdown of the iBRB.
Retinal ECs in the iBRB are potential targets of the inflammatory markers such
as eicosanoids, cytokines, and the growth factors. Chronic HgA upregulates
inflammatory mediators which in turn induces leukocytes adhesion to ECs which further
injures the iBRB [68-70]. Breakdown of the iBRB as a result of cytokines release
generate an inflammatory response which further increases the release of the
inflammatory mediators, thus additionally exacerbating the situation. Leukocytes
adhesion also induced retinal hypoxia, the retinal hypoxia also leads to abnormal blood
vessel growth concurrently [71, 72].

Diabetic Retinopathy
The earliest sign of DR is a dysfunctional iBRB. DR is characterized by loss of
pericytes [73, 74], basement membrane thickening, microaneurysms [75], acellular
capillary, and iBRB breakdown. The factors that contribute to capillaries degeneration
are occlusion of the capillary’s lumen by white blood cells or platelets, and death of
capillaries cells due to hyperglycemia. There are many biochemical mechanisms
proposed for the pathogenesis of DR, although the etiology is yet to be precise. Chronic
HgA is the main factor contributing to the development of DR, and its complications. The
earliest retinal changes due to HgA are biochemical, cellular, or hemodynamic in nature.
Metabolic deregulation affects
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the neurons and the support cells of the retina. However, it is the microvessels that in fact
are affected the most. They [capillaries] dominate clinical events of the disease and are
also the focal point for the development of macular edema and neovascularization. In the
early stages of DR, functional cells of the retina exhibit changes such as glial cell
reactivity, alterations in glutamate metabolism, and neuronal cell death [76-78]. Until the
development of retinopathy, vision is normal in diabetics patients if they don’t have any
other concurrent eye problems. DR is divided into two stages: Non-proliferative DR
(NPDR) and Proliferative DR (PDR). After five years of living with diabetes, NPDR
symptoms start to appear. NPDR is intraretinal microvascular derangement that could
progress to diabetic macular edema (DME) (accumulation of fluid in the macula) or PDR
(extraretinal neovascularization). Progressive retinal ischemia and the rise in local growth
factors are the primary mechanisms outlined in the development of PDR. PDR is new
growth of blood vessels in the retina or optic disc that extends along the retinal surface or
into the vitreous cavity [79, 80]. Pathogenesis of PDR involved hypoxia that results in
low perfusion of retinal tissue, thus prompting neovascularization (directly related to
VEGF). Initially, the new blood vessels are barely visible, then they gradually increase in
size, and could become as large as a retinal vein. New blood vessels are usually
asymptomatic [81, 82]. The new growth of blood vessels is gradually accompanied by
fibrous proliferation, and it is this contraction of the fibrous tissue that can can lead to
retinal detachment and vitreous hemorrhage. These two traits more often than not lead to
vision loss in PDR.
The cornerstone of NPDR treatment is glycemic control while managing PDR
has the following aims: decrease the growth of blood vessels, contraction of vitreous, and
fibrovascular proliferation. Photocoagulation is the gold standard for PDR treatment.
However, photocoagulation comes with complications since high density/intensity laser
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may cause loss of night and colored vision [83] and reduced contrast sensitivity [84].
Other treatments for PDR include VEGF Inhibitors and Vitrectomy [85].
Many biochemical mechanisms have been put forward to explain the vascular
pathology of DR. Among the proposed pathways are aldose reductase (AR), AGEs
formation, reactive oxygen intermediates elevation, PKC, and the inflammation.

DR-Biomolecular Mechanisms
AR Pathway. Retinal capillary cells (endothelial, and pericytes), and glial cells expressed
AR and thus are subjected to the polyol pathway [86]. The polyol pathway or the AR
pathway is induced during high blood glucose levels [87]. First, AR reduces glucose into
sorbitol (nicotinamide adenine dinucleotide phosphate hydrogen; NADPH serves as a
cofactor). Next, sorbitol dehydrogenase (SD) reduces into fructose (nicotinamide adenine
dinucleotide (NAD+) serves as a cofactor). Since sorbitol cannot cross across the cell
membrane it accumulates intracellularly inducing an osmolality effect [87]. Next, as the
substrates use NADPH and NAD+ in this pathway, they are quickly depleted thus
decreasing the body’s capacity in responding to the OS. For example, the use of NADPH
hinders its bioavailability for glutathione reductase [88]. NADH/NAD+ ratio is increased
due to the use of NAD+ by SD. Further, NADH oxidase could also use NADH as a
substrate to increase the generation of ROS [89]. Additionally, fructose can further
metabolize into fructose-3-phosphate, and 3-deoxyglucosone, both of which can become
the glycosylating agents [90, 91]. This pathway generates osmolality effects, glycating
agents, and OS. Studies have shown that inhibition of AR in diabetic animal models
prevents retinal injuries [92]. Although clinical trials with AR inhibitor have not been
significantly fruitful [93].
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AGEs. Amine group modification of a protein by reducing sugars such as glyoxal, 3deoxyglucosone, and methylglyoxal, generate AGEs [94]. Retinal levels of AGEs
increase in diabetic’s rat model and humans [95]. The presence of AGEs on the basement
membrane interferes with pericytes and ECs communication. AGEs bind to their
receptors, activate NF-B, and generate ROS.

PKC: PKC is a serine/threonine-protein kinase that mediates many cellular signal
transduction pathways [96]. The various isoforms of PKC are activated via diacylglycerol
(DAG), calcium, and other substrates. HgA increases the expression level of DAG [97].
Studies reported that DAG levels have increase in the retina of the diabetics [98].
Activation of PKC increases albumin permeability across ECs [99, 100] and hinders
vasodilation via depleting nitric oxide (NO) levels. PKC also caused the loss of pericytes
[101].

OS: The retina is perfused 300 times more than both the heart and the cerebral cortex,
thus making it more susceptible to OS; phototransduction, and shedding of POS by the
RPE also contribute. ROS, free radicals in the form of hydroxyl radicals, and superoxide
anion are very reactive, mainly due to the unpaired electrons in their valence shell [102].
Many factors lead to the generation of ROS including the mitochondria electron transport
chain [103]. Under normal conditions, the mitochondria contribute the most to ROS
levels. The process of aging, and inflammation can disrupt homeostasis by generating
more ROS than the body can remove thus inducing the process called OS [104, 105]. The
body uses antioxidant (vitamin C and E, superoxide dismutase; SOD, and catalase) to
neutralize ROS [102]. Once the body anti-oxidant system is overloard that create OS.
HgA activates PKC, polyol flux, and AGEs that generate ROS [106].
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Increased ROS injure ECs, activate NF- [107-110], and recruit neutrophils [111].
There is evidence that OS is the main factor that triggers the chronic inflammation
response in the retina [112]. Inflammation increases expression of inflammatory
mediators, promotes leukocyte adhesion to retinal capillary walls, and occludes retinal
capillaries causing hypoxia. Eventually, breakdown of the iBRB happens.

Inflammation
Basics Concept in Immunology. Immune privilege of the eye is maintained by the BOB,
DIE, and the lack of direct lymphatic drainage from the eye [113]. The immune system
consists of two parts: innate and adaptive. The innate immune pathway is immediate and
nonspecific. Pattern recognition receptors (PRR) recognizes the conserved microbial
patterns and triggered a nonspecific inflammatory reaction; for instance, toll-like
receptors (TLR) recognize LPS of the gram-negative bacterial outer membrane [114]
which activate immune cells, monocytes, macrophages, natural killer (NK) cells,
polymorphonuclear cells, eosinophils, and basophils. The adaptive immune response,
however, is more complicated and elaborated below.

Adaptive Immunity. The key components include B and T lymphocytes, which contain
receptors (immunoglobulins; Igs) for recognizing antigenic epitopes [115]. Igs are
expressed by B cells and T cells in the absence of exogenous stimulation. Igs contains
unique configurations that recognize specific antigens. Each group of lymphocytes
depicts the same cell surface receptors to identify multiple epitopes, and to accomplish
this billions of lymphocytes are generated.
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Figure 3. Mechanism of Diabetic Retinopathy Pathology. Hyperglycemia during
diabetes activates many pathways such as PKC, AGEs, and polyol. These pathways
induce oxidative stress, and inflammation in the retina. Inflammation contributes to
retinal vascular occlusion, and dysfunction of retinal capillary cells that lead to the
development of DR. DR starts as NPDR, then gradually progress to PDR or DME or
both.
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After maturation in the thymus (T cells) or bone marrow (B cells), lymphocytes
remain in the dormant or G0 phase of the cell cycle until an antigen binds to its receptor
(called naïve). Molecule binding to a B or T cells triggers an immune response to destroy
the bound molecule or the antigens. If the molecule is pathogen-derived then it leads to
the destruction of the pathogen. If it is a cell-derived then it leads to autoimmunity, and
therefore occurrence of the tissue injury.
Activation of a naïve lymphocyte leads to the proliferation of that lymphocyte
which recognizes a specific epitope. T cells (CD4+ and CD8+) become cytotoxic once
activated or differentiate into effector cells. CD8+ T cells become cytotoxic once
activated. CD4+ T cells via interleukins (IL) differentiate into one of three effector T cells
(Th1, Th2, and Th17). IL-4 leads to Th2, IL-12 leads to Th1 [116], whereas IL-1 and IL23 lead to Th17 differentiation [117]. Th1 and Th2 cells become memory cells that
trigger the immune response if the antigens reappear. Th1 secretes cytokines that target
macrophages, and other cells involved in the immune response. Th2 stimulates B cells
proliferation to produce antibodies to kill the invader. Th17 cells produce IL-17 [118],
and IL-23 to fight fungal and bacterial infections.
The adaptive immune response is divided into three parts: antigens recognition,
transportation, and presentation to lymphocytes. Antigens are recognized, processed, and
presented (through MHC) to lymphocytes by dendritic cells, and macrophages. There are
differences in the process of antigen presentation. B cells can engage with naïve antigen
directly but T cell receptor (TCR) can only recognize peptide fragments presented with
MHC molecules (Class I or II). MHC Class I molecules (expressed in most cells) present
peptides derived from protein degradation in the cytoplasm (intracellular antigens). MHC
Class II molecules (expressed in APCs and lymphocytes) present peptides derived from
phagocytic vesicles (extracellular antigens). APCs provide co-stimulation needed for
26

lymphocytes activation [119]. APCs upregulates CD80, CD86, ICAM-1, and CD40
molecules to function as ligands for lymphocytes receptors. APCs also secrete soluble
cytokines such as IL-12, IL-6, IL-10, and IL-1 to stimulate lymphocytes further.
CD4+ T-cell activation leads to CD4+ proliferation and cytokines secretion such
as IL-2, IL-3, granulocyte-macrophage colony-stimulating factor, interferon-gamma
(IFN-), and IL-4 which serves as growth and stimulation factors for lymphocytes and
APCs. IL-2, IFN-, and IL-4 promote differentiation of CD8+ T lymphocytes to mature
cytotoxic T lymphocytes. Cytokine production by CD4+ T cells also promotes activation
and differentiation of B lymphocytes. IL-2, and IFN- stimulate B cell to produce
immunoglobulin g (IgG) while IL-4, 5, 6, and 10 stimulate the production of IgG, IgE,
and IgA antibodies.
Final products of processing in the lymphoid tissues are activated effector CD4+,
CD8+, and B cells. These cells travel through the blood to execute the response. Activated
B cells secrete antigen-specific antibodies to kill the target directly. Activated CD4+ T
cells secrete cytokines, and IFN-, which in turn recruit the cells of the innate immune
system to the site of the antigen. Activated CD8+ lyse target cells and produce
proinflammatory cytokines, especially IFN-. Cytokines involved in the response
perpetuate a positive feedback loop at the target sites. Blood vessels become leaky,
vascular endothelial cells display ligands that bind to immune cells receptors, and
chemokines secreted by local inflammatory cells to attract more immune effector cells
and the cascade continues [119].

Inflammation in DR
DR is regarded as an inflammatory disease due to the presence of inflammatory
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mediators that are found in the vitreous and the retina of diabetic animals models and the
patients. The increase in expression of these markers is associated with a dysregulation in
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-) [120].

NFKB. NF- is a family of five transcription factors that has structurally related
subunits: NF- 1 (p50), NF- 2 (p52), RelA (p65), RelB, and c-Rel. Once activated,
they form either hetero or homodimers and get translocated into the nucleus. In the
nucleus, they bind to  DNA binding sites and increase the expression of NF-
targeted genes [121].
NF- regulates gene transcription that plays key roles in inflammation, immune
cell development, cell cycle, proliferation, and cell death [122, 123]. NF- is pertinent
for both innate and adaptive immune cell functions. It regulates survival, activation, and
differentiation of both innate and adaptive immune systems cells. NF- activation
induces expressions of pro-inflammatory genes, cytokines, chemokines,
immunoreceptors, apoptosis, proliferation, and inflammasome [120].
Stimuli that activate NF- include TLRs, antigen receptors, OS markers,
genotoxic stress, cytokine, and growth factors. There are two types of NF- activation:
specific and non-specific. Both are influential in regulating inflammation and immune
response [124]. The NF- subunits reside in the cytoplasm where they remain inactive
via inhibitory proteins of the I (IB) family [125]. Activation of NF-B requires IB
kinase (e.g., IKK) to phosphorylate the IB which then is recognized by the E3 ligase
to degrade the inhibitor. This process induces the translocation of NF- heterodimers
(e.g., p50/RelA) into the nucleus [126-128], where they bind to DNA sequences known
as  sites [121].
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Figure 4: Immune System Mechanism. The immune system consists of two parts:
innate and adaptive. The innate system is the primitive and nonspecific one and uses
dendritic cells, monocytes, macrophages, and other immune cells to destroy the invading
pathogen(s). On the other hand, the adaptative system uses the bone marrow-derived (B
cells) and thymus-derived Treg cells, innate immune cells, antibodies, and immune
ligands (e.g., cytokines) to lyse antigens.
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In contrast, the non-specific pathway responds to a specific set of stimuli, such as
receptor-activated nuclear factor kappa B (RANK) [129, 130]. The subunits activated in
this pathway are RelB and p52 and require IKK and cleavage of p100 to p52. First,
processing of NF- 2 (p100) occurs [129] followed by translocation of p52/RelB into
the nucleus [129, 131]. The specific pathway is involved in all aspects of the immune
system, and the non-specific is complementary to the adaptive immune system regulation
[130]. NF- is regulated primarily via a negative feedback loop wherein activation of
NF- induces production of IB [132]. Activation of NF- mainly heterodimerizes
into p50-p65 thus transcribing the pro-inflammatory proteins (iNOS, ICAM-1) [133].
Inflammation serves as a protective mechanism against tissue damages and
infections under physiological conditions, however it may be detrimental in the long
term. Deregulation of inflammatory responses causes damages to host tissues that could
lead to the development of short or long-term inflammatory diseases. Chronic
inflammatory conditions such as diabetes involve deregulation of NF- activation.
Dysregulation of NF- induces an excessive increase in inflammatory proteins. Recent
studies have shown an increase in inflammatory mediators such as COX-2, and iNOS in
the retina and vitreous of DR animal models and the patients, as stated earlier. These
molecules are consistent with the innate immune pathway. Also, other studies have also
shown that retinal inflammation is also associated with the activation of NF- [134].

iNOS. Inducible Nitric Oxide Synthase (iNOS) meditates NO production from Larginine. Regular production of NO is generated via two NO synthases (neuronal and
endothelial). While iNOS generation of NO involves solely in inflammation. An elevated
level of NO is associated with many inflammatory diseases, e.g., inflammatory bowel
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disease [135-137]. iNOS has high expression in activated immune cells and low to no
expression in most resting cells [135]. Activated NF- induces transcription of iNOS
[120]. Studies in the literature shows an increased iNOS levels in the retina of diabetic
animals, which associated with apoptosis of retinal cells, leukostasis, and iBRB
breakdown [138]. iNOS elevation is very well present in the retina of human patients
[139-142]. iNOS has also been shown to mediate the production of oxygen radicals.
iNOS generates superoxide anions in macrophages [143]. NO could react with
superoxide anion to form peroxynitrite, and injure macromolecules inside the cells.
Increase production of NO could also result in nitration and nitrosylation of the retinal
proteins, which is also toxic. NO elevation generated by iNOS causes the loss of
pericytes, and retinal thinning (GCL, IPL, and OPL). Studies of retinal cells exposed to
high glucose (HG) demonstrated that NO (particularly iNOS generated) regulates
prostaglandin E2 (inflammatory marker generated by COX-2) expressions. iNOS is also
associated with GCs loss in Akita mice after 22 weeks of diabetes [144]. Inhibitor of
iNOS (aminoguanidine) has shown to decrease vascular injuries associated with DR in
rodents [145-147]. Studies of retinal cells exposed to HG demonstrated that NO
(particularly iNOS generated) increases the expression of cyclooxygenases-2 (COX-2)
[144].

COX-2. Eicosanoids are signaling molecules that are derived from arachidonic acids such
as prostaglandin (PG), thromboxane, and leukotrienes. Cyclooxygenase enzymes mediate
the first two steps of eicosanoids synthesis. Many isoforms have been identified, such as
COX-1, and COX-2. COX-1 is expressed in most tissues and it functions to maintain PG
production. PG is known to regulate renal blood flow, immune responses, and
inflammation [148-152]. In the eye, it is involved in ocular inflammation [153], IOP
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[154], corneal neovascularization [155], corneal edema [156], retinal blood flow [157],
iBRB, and BOB impairment [158].
COX-1 maintains physiological productions of eicosanoids, whereas COX-2
eicosanoid production occurs in the presence of inflammation. COX-2 is generally absent
from most tissues, but its expression is increased in the presence of bacterial LPS and
proinflammatory cytokines; thus, COX-2 has high expression in immune cells
(monocytes, macrophages, and ECs) [159]. NF- activation upregulates COX-2 gene
expression in retinal cells [160]; and is associated with iBRB breakdown [161].
Interestingly, COX-2 expression is elevated in the retina of Akita mice [162]. Another
inflammatory mediator that is positively regulated by NF- and has high expressions in
the retina of DR is the intercellular adhesion molecule-1 (ICAM-1).

ICAM-1. ICAM-1 is a membrane-bound glycoprotein and serve an important function in
immune responses, e.g., leukocyte trafficking [163]. ICAM-1 is consisted of five Ig
domains, a transmembrane domain, and a linker in the cytoplasm that interacts with actin
molecules [164]. It is expressed in ECs, leukocytes, platelets, epithelial cells, and glial
cells. Its expression is low when inflammation is not present. It performs functions in
immune cells such as adhesion, migration, and aggregation [165]. Leukocytes adhesions
(leukostasis) to retinal endothelium is associated with iBRB breakdown [166].
Leukostasis is elevated in the retina during hyperglycemic conditions [166].
Leukostasis in retinal vessels is mediated by elevation of ICAM-1. Activation of NF-
increases ICAM-1 expression [167]. Leukostasis elevation is linked with an increase in
vascular permeability [168]. Inhibition of ICAM-1 reduces leakage and leukocytes
adhesion in the retina of diabetic rats [169].
33

Leukostasis in retinal vessels is mediated by elevation in ICAM-1 and CD18
leucocytes integrin [170]. Streptozotocin (STZ) induced diabetes in mice that are
deficient in ICAM-1 shown less leukostasis in retinal vessels [171]. STZ induced WT
C57BL/6 J mice exhibited increased expression of ICAM-1 in their retina [169].
Activated leucocytes injected into the retina of healthy mice show increased leukostasis
via ICAM-1 [172] and inhibition of ICAM-1 decreases leukostasis in the retina of
diabetic rats [173].

Pyroptosis
Pyroptosis is a cell death pathway due to inflammation. It involves the assembly
of an inflammasome, activation of caspase 1 (Casp-1), IL-1 and IL-18. Pathogenassociated molecular patterns (PAMPs) and danger-associated molecular patterns
(DAMPs) induce inflammasome assembly [174]. Inflammasome contains a nod-like
receptors protein (NLRP) family receptors (e.g., NLRP3), adaptor protein ASC
(apoptosis-associated spec-like protein containing CARD) and pro-caspase 1.
Inflammasome plays a vital role in the innate immune system against infections, but its
deregulation could lead to the development of autoimmune and inflammatory diseases
also [175]. NF- regulate inflammasome assembly [175]. NF- is a known activator
of nod-like receptor pyrin domain 3 (NLRP3) [176, 177]. NF- induces pyroptosis
through activation of NLRP3 [178].

NLRP3. Nod-like receptors (NLRs) are PRR and generally located in the cytoplasm, thus
making it possible to detect pathogenic invaders inside the cell [179]. Most NLRs are
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Figure 5. Nuclear Factor Kappa B Activation. NF- homo/heterodimerizes and
translocate into the nucleus once activated. They bind to B DNA binding sites and
induce the transcriptions of inflammatory mediators such as iNOS, COX-2, and ICAM-1.
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active during the innate immune responses, and are activated via PAMPs, DAMPs, cell
stress, or ROS. NLRs family have 14 distinct members, named NLRP1 to NLRP14 [180].
NLRP3 can also be activated by extracellular ATP, and UVB radiation [180]. NLRs form
complexes known as inflammasomes, which cleave casp-1, and casp-1 cleaves
interleukins-1 beta (IL-1), and interleukins 18 (IL-18) [181]. NLRP3 is the most studied
NLRs and various stimuli could trigger its activation. It is involved in multiple
pathologies, e.g., type II diabetes, and obesity [182]. NLRP3 structure has three distinct
domains: pyrin domain (PYD), leucine-rich repeat (LRR) domain, and a nucleotidebinding domain (NBD) [183]. NLRP3 inflammasome is consisted of NLRP3, ASC, and
Casp-1. Stimuli activate NLRP3 via interaction with the LRR, then the PYD and the
NBD are free to interact with other entities. Through the NBD domain, NLRP3
oligomerizes and then recruit ASC to form the NLRP3-ASC complex [184]. ASC then
recruits casp-1, casp-1 auto processed, and cleaved pro-IL-1 to IL-1 and IL-18 [185,
186]. The NLRP3 activation mechanism is yet to be defined though. A common
mechanism has been suggested that the extracellular ATP stimulates purinergic P2X7
ATP-gated ion channel leading to the efflux of K+ ions. Pannexin-1 membrane pore
protein is recruited into the target cell and that can lead to the activation of the assembly
of the NLRP3 inflammasome [180].
HgA can upregulate NLRP3 expression in cultured Müller cells [180]. The role
NLRP3 and inflammasomes play in DR is still under intense investigation. Hui Chen et
al. reported a high level of NLRP3 expression in the blood from diabetic patients. They
speculated that its activation could be due to elevation in ROS that could presumably be a
byproduct of other molecular mechanisms, e.g., polyol pathway [187].
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Casp-1. Casp-1 is part of the caspase family of cysteine proteases that involve either (a)
an increase activation of proinflammatory cytokines or (b) cellular death by apoptosis.
However, casp-1 can participate in both cytokines activation and apoptotic cell death.
Casp-1 resides in the cytoplasm until activation by NLRP3, and then it heterodimerizes
into two subunits (10 & 20 kDa) [180]. Casp-1 activation induces expression of both IL1 and IL-18 [188]. HgA has been shown to activate casp-1 in the retina of diabetic mice,
patients, and Müller cells [188]. Inhibition of casp-1 by minocycline prevents the
degeneration of retinal capillaries cells induced by the development of diabetes [188].
Casp-1 activation induces expression of both IL-1 and IL-18 [188].

IL-1 IL-1 is part of the IL-1 family which is consisted of 11 different ligands and
receptors. These ligands function to induce inflammation or anti-inflammation
independently in the blood or tissues. IL-1 is one of the first ILs discovered. IL-1 is
synthesized as pro- IL-1 , which remains inactive until it is cleaved via casp-1 to
produce mature IL-1 [180] IL-1 binds to its receptor (IL-1 receptor type 1; IL-1R). IL1 action is regulated via IL-1R antagonist, which competes for the same receptor. IL1 functions in the extracellular milieu where it resides within the cytosol and is secreted
upon stimulation or cell death. Many different retinal cells produced IL-1 including
microglia, and the astrocytes [189]. IL-1 played a crucial role in innate immune
response, helps fighting pathogens, and tissue repair. IL-1 induces the activation of
microglia and other retinal glial cells along with proinflammatory mediators. Thus,
prolonged exposure or overexpression of IL-1 can lead to tissue damage. Elevation of
IL-1 expression was reported in the retina of diabetic rodents experimental models as
early as eight weeks after the onset of HgA. IL-1 has also been reported in the
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vitreous of patients with DR. IL-1 administration in the vitreous of nondiabetic rats led
to apoptosis of retinal capillary cells via activation of NF-B [189, 190]. Susana Vallejo
et. al reported that anakinra (inhibitor of IL-1R) prevented impairment of ECs in STZ
induced diabetic rats via NF-B activation and subsequent increase in iNOS production
[191]. Literature also reported that constant exposure to IL-1 led to ECs impairments
and degeneration of blood vessels [188]. Other studies reported that HG increased the
expression of IL-1 in Müller cells [192]. In the retina of diabetic mice, casp-1 and IL-1
have been detected as well [193]. These markers have also been shown to be implicated
in the death of microglia and Müller cells [194]. Furthermore, IL-1 increases the
expression of COX-2 and adhesion molecules in ECs [180].

iBRB and DR
Recent studies reported existence of reduced gap junction intercellular
communication (GJIC) thus highlighting the iBRB dysfunction. Cx43 expression in
numerous retinal cells is downregulated during HG environment [195]. Studies have
shown that HG downregulates Cx43 expression levels in the mitochondria, potentially
promoting endothelial and pericytes cell death [196, 197]. HgA showed to impair Cx43
expression, thus decreasing the activity of GJ, and the decrease in expression of the TJ
molecules in ECs, and a subsequent cell death phenotype [55].
Studies in astrocytes depicted that activation of NF-B by TLR-3 protein leads to
a decrease in the expression of Cx43, thus reducing GJIC [198]. Kunihiko Nagasawa et
al. reported that Cx43 is associated with TJ proteins in the blood-brain barrier (BBB)
[199]. Studies in rat retinal ECs depicted that HG decreased Cx43 expression, and this
decrease in Cx43 expression downregulated TJ protein, particularly occludin, thus
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impairing cell permeability but the mechanism(s) is yet to be discovered [200].
HgA decreases expression and redistribution of occludin [58, 201]. Ermelindo
Leal et al. found that increased expression of NO generated by iNOS reduced the
expression level of occludin in STZ induced diabetic rats, therefore leading to the
breakdown of the iBRB [201]. NF-B activation induced by TNF- can internalize
occludin which may disrupts the TJ barrier between epithelial cells in inflammatory
bowel disease [202].
Loss of pericytes occurs during HgA in part due to a reduction in PDGF-B levels.
Additionally, a concomitant loss of both the pericytes and ECs could result in acellular
capillaries (no ECs or pericytes). This particular aspect increases the likelihood of
microaneurysm formation and bleeding in the retina which would indicate iBRB
breakdown. In the presence of IL-1, activated pericytes secrete various cytokines and
chemokines, including IL-1. It secretes these factors to attract immune cells to the sites
of inflammation. Pericytes increase the expression of ICAM-1, other adhesion molecules,
and at the same time downregulate the TJ molecules [203] thus facilitating immune cell
passage through the endothelium.
HG leads to the death of Müller cells via activation of casp-1 and IL-1 .
HgA increased the expression of IL-1 in Müller cells [61] and its secretion. IL-1 then
bound to IL-R1 on ECs and increased the expression of ICAM-1 [60]. Studies have
shown that HgA impaired Müller cells uptake of glutamate, which could lead to
glutamate toxicity in diabetic rats. HgA also reduced potassium uptake, further
exacerbating the glutamate toxicity by increasing the neuronal excitation [61]. Diabetes
impairs Müller cells function via decreasing expression of glutamine synthase, and the
activity of the glutamate transporters [204]. Selective ablation of Müller cells
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results in BRB in Rlbp-LacZ mice which also impairs the A-wave and B-wave responses
of the mice [204]. HgA significantly impaired communication between astrocytes by
reducing Cx43 expressions and other GJ as early as four weeks post STZ treatment in
rats. These animals also depicted the death of astrocytes after six weeks of HgA [205].

Inflammation and Intraocular Pressure
The aqueous humor is secreted by the ciliary body (CB) epithelium and it is the
key factor that determines the dynamics of intraocular pressure (IOP). It is the plasma
components of the CB that help secrete the aqueous humor into the posterior chamber
(PC) which then circulate into the anterior chamber (AC). From there the aqueous humor
drains into the trabecular meshwork and Schlemm’s canal. The cells in the CB
synthesized the aqueous humor in three steps. First, when the blood flows through the CB
the plasma in form an ultrafiltrate is made due to the pressure gradient between blood
flow and the interstitial of the ciliary body. Last, the epithelium of the CB transports the
aqueous humor from its basal end to its apical surface actively (and selectively) and then
pumping it into the PC. Systemic blood pressure has very little to do with aqueous humor
synthesis, although the first step has to do with blood flow, only about 4% of plasma is
being filtered [206].
Circulation of the aqueous humor generates the IOP within the AC. IOP plays a
crucial role in the pathophysiology of glaucoma. An increase in IOP is a key risk factor
for glaucoma, although some patients with normal IOP may have glaucoma, while others
with high IOP may not have glaucoma. One factor that is associated with an increase in
IOP is increased resistance in outflow [206].

HgA and IOP. Multiple demographics studies concluded that there is an increase
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in IOP in diabetic patients than nondiabetic patients, and that an increase in IOP is
independent of open-angle glaucoma. The mechanism has not yet been determined
though. It is speculated that HgA causes an osmotic gradient that shifts fluid between
plasma and intraocular fluids thus elevating the IOP [207]. A Japanese study found a
significant correlation with IOP and HBA1c levels in patients with DR [207]. Similarly, a
Chinese population study found an association between DM with high IOP (>21 mmHg)
[208]. Demographic study in Singapore also found an association between elevated IOP
and DM. Even after accounting for the difference in central corneal thickness, which is
higher in diabetics individuals, the increase in IOP was independent of the development
of glaucoma.

JSH-23 Mechanism
4-methyl-N1-(3-phenyl propyl)-1, 2-benzenediamine (JSH-23) is a selective
inhibitor of NF--p65/p50. It stops nuclear translocation of NF--p65/p50 and thus
helps stop the transcription of its target genes [209]. JSH-23 has an IC50 of 7.1 M for
NF-B nuclear translocation and transcriptional activity on macrophages RAW 264.7
stimulated by LPS. Kumar et al. showed that oral administration JSH-23 inhibits NF-B
in STZ induced male Sprague Dawley rats, and was able to decrease the expression of
COX-2, iNOS in the sciatic nerve and improve nerve function [210]. When JSH-23 was
used in a chronic mild stress model to inhibit the effect of NF-B, it was able to decrease
inflammatory mediators and increase anti-oxidant defense in the hippocampus [211].
After sepsis, LPS induced cardiac injury through differentiation of M1 macrophages.
JSH-23 inhibits LPS induced cardiac injury in a sepsis animal model [212]. Transition
metal ions activate NF-B and NLRP3 in bone marrow-derived macrophages, thus
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pyroptosis and again JSH-23 was shown to inhibit NLRP3 activation via inhibiting
phosphorylation of NF-B in macrophages after transition metal activation [213].
Cisplatin activates NF-B and induces acute kidney injury by necrosis and apoptosis of
proximal tubular epithelial cells. JSH-23 reduced many of the response genes of the NFB activation, including casp-1 in C57BL6J mice treated with cisplatin [214]. To our
knowledge, JSH-23 has not yet been used to decrease NF-B activation in DR or Akita
Mice. Therefore, to test our hypothesis, we used the Ins2Akita mouse (Akita) that has been
well-characterized as an excellent model system to study T1D. Akita harbors a missense
mutation in the Insulin 2 gene, which leads to a conformational change in insulin protein,
causing it to accumulate in pancreatic β-cells. Accumulation causes loss of cellular
function, decreased cell density, and, finally, cell-death leading to HgA because of insulin
deficiency [144, 215-217]. These mice become hyperglycemic after four weeks of age.
HgA-induced retinal pathology ensues after 12 weeks, starting with appearance of
acellular capillaries, and infiltration of the leukocytes into vascular walls [144, 218, 219],
increased in vascular permeability, degeneration of astrocytes and microglia, thinning of
the IPL, INL, and loss of RGCs [219]. The Akita model has many vital advantages. It has
an autosomal dominant mutation with stable hypoinsulinemia, and lacks systemic
immunologic alterations. It is fertile, and its background does not contain the rd (pde6)
variations; such modification are responsible for photoreceptors degeneration [144].

Summary. HgA in Type I Diabetes (T1D) induces retinal inflammation via NF-B
activation. Retinal capillary cells such as endothelial, pericytes, and glial cells are critical
parts of the iBRB but remain potential targets of inflammatory mediators. Inflammatory
mediators also targeted junctional molecules thus impairing the cell-cell
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communication and the paracellular transport. NF-B increased the pro-inflammatory
genes, which induced iBRB breakdown. Thus, we proposed that the inhibition of NF-B
p65 subunit with JSH-23 to prevent retinal microvascular impairment in the retina of
Akita mice.
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Figure 6. Molecular Structure of JSH-23. JSH-23 inhibits the nuclear translocation of
NF-B p65 subunit and its transcriptional activity.
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FIGURE 6
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Figure 7. Summary. iBRB is consisted of endothelial, pericytes, and glial cells. The
ECs and their TJ regulate transcellular and paracellular transport into the retina. HgA
activates NF-B, which then increases the expression of inflammatory mediators thus
causing leukostasis, vascular occlusion, and the iBRB breakdown.
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FIGURE 7
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Figure 8. Summary of Background. HgA (in T1D Akita mouse model) dysregulates NF-B.
NF-B overexpression increases the production of pro-inflammatory molecules from its target
genes that lead to degradation of the junctional molecules in the affected retinae. As a result, the
iBRB is impaired, which eventually results in the vision loss or even blindness in the susceptible
diabetic patients.
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FIGURE 8
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CHAPTER II
HYPOTHESIS AND SPECIFIC AIMS

Key Objective
The goal of this study is to determine the effects of chronic inflammation in
impairing retinal capillary vessel in Akita (T1D model) and to investigate whether JSH23 can inhibit these injuries.

Hypothesis
During Diabetes (T1D), vision loss is due to retinal vascular leakage by an
increase in inflammatory mediators (NF- p65, COX-2, INOS, and ICAM-1) which
lead to an increase in retinal vascular permeability, intraocular pressure, and vision loss.
Therefore, treatment with inflammatory inhibitor (JSH-23) will mitigate this vision loss.

Specific Aims
Specific Aim 1: To determine whether there is an increase in inflammatory
mediators (NF- p65, COX-2, INOS, ICAM-1) in Retina of T1D mice and
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whether inflammatory inhibitor, JSH-23, mitigate this increase in inflammatory
mediators. (Chapter 3)

Specific Aim 2: To determine whether T1D increases retinal vascular permeability by
decreasing expression of junctional molecules (Occludin, Connexin 43) and whether
treatment with JSH-23 mitigate this increase in retinal vascular permeability. (Chapter 3)

Specific Aim 3: To determine whether T1D leads to vision loss in part by increase
retinal vascular permeability and ocular pressure and whether treatment with JSH-23
mitigate this vision loss and retinal vascular permeability. (Chapter 4)
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CHAPTER III
JSH-23 DOWNREGULATES NF-B AND INCREASE EXPRESION OF
JUNCTIONAL MOLECULES IN THE RETINA OF AKITA MICE

Introduction
T1D is a chronic illness that is diagnosed during childhood. It occurs in ~1:400600 American children [220]. A recent disturbing trend is a 15-20% increase in new
diagnoses of T1D under age 5 [221, 222]. The reason for this alarming increase in youths
is debatable. Clinically, diabetes management has proven challenging for a variety of
reasons, including physiological factors such as increased insulin sensitivity, especially in
children [223]. T1D microvascular complications included DR which is divided into
NPDR and PDR. DME can develop in either of the two stages [224]. Other serious
complications include retinal detachment, and blindness.
DR is a leading cause of blindness in the working age adults. In its advanced
form, DR can lead to blindness due to the development of DME, and cataract. Current
clinical interventions vary depending on the extent of disease progression. Tight bloodglucose control and dietary measures may help slow down the disease progression in
some people however; glucose control does not stop disease progression to DME or PDR.
Patients may require laser surgery to seal the leaking blood vessels in their eyes or to
discourage other vessels from leaking further. VEGF inhibitor injection into the eye may
also be needed to decrease unabetted underlying inflammation or to stop the formation of
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abnormal vessels. Leakage from retinal vessels leads to a fresh wave of inflammatory
swelling that invariably results in a cloudy or blurred vision. Even worse, a surgical
procedure may be warranted to repair a detached retina. If left untreated, DR causes
permanent blindness [225, 226].
Current interventions do not adequately address the “retino-vascular” signature
pathology that underlies the initiation, progression, and maintenance of the DR
phenotype. Furthermore, they fail to restore loss vision in the majority of patients. The
etiology of DR is not fully understood although many pathways have been proposed for
the development of DR pathology such as polyol flux, hexosamine, AGEs, and OS. DR is
regarded as an inflammatory disease due to the presence of various inflammatory
mediators found in the vitreous and the retinas of diabetic animals and humans [227]. An
increase in the expression of inflammatory mediators is directly associated with NF-κB
activation [120]. NF-B is a dynamic transcription factor that orchestrates complex
biological processes, including the inflammatory response itself [228]. Owing to its
upstream role in cell-signaling, NF-κB is considered a central component in the
inflammatory response, directing the elaboration of cytokines, and responses to stress,
free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial, and viral
antigens.
NF-κB is the first responder to harmful stimuli for cells/tissues. It shuttles
between cytoplasm and nucleus to initiate and then help execute a robust genetranscription program. It consists of a family of structurally related transcription factors
viz. NF-1(p50), and RelA (p65) that can form hetero- and homodimers and translocate
to the nucleus upon activation [121, 209, 229, 230]. There is a presence of a chronic
inflammation in diabetics individuals, which could be mediated by dysregulations in NF54

 signaling [120]. It has been shown that NF- increased the pro-inflammatory genes
in the retina of both diabetic animal models and patients [231]. It also induced the
activation of pyroptosis [194]. It seems that the sustained inflammation could lead to
degradation of the iBRB. The BRB consists of the iBRB and oBRB which regulates the
movement of ions, and solutes into the retina. The iBRB maintains harmony between TJ
molecules, and retinal ECs and any kind of impairments can lead to fluid accumulation in
the retina [232]. In diabetes, there is a decrease in expression in junctional molecules in
the presence of sustained inflammation [233].
As DR is a significant complication of an underlying autoimmune disease, we
tested our hypothesis that systemic inhibition of NK-κB activity in a T1D model could
help mitigate inflammation-induced microvascular changes in the retina that we believe
are responsible for vision problems. And we know that the inflammatory mediators are
elevated in the retina of DR; and are associated with iBRB breakdown [234]. Therefore,
we hypothesized that pre-empting inflammation by inhibiting NK-κB activity with JSH23 would certainly help mitigate the microvascular alterations in the diabetic retina.
Moreover, JSH-23 has been demonstrated to inhibit the nuclear translocation of NF-p65 and thus inhibit its transcriptional activity [209]. The objective of this study is to
investigate the effect of how suppressing inflammation could potentially prevent the
development of DR in the Akita mouse model.

Methods
Animal Genotyping and Maintenance of the Animals. Male C57BL/6J (WT) and
Ins2Akita+/− mice (Akita) were purchased from the Jackson Laboratory (Bar Harbor, ME).
All animals were ∼24-26 weeks old and were maintained in a 12:12 hour light-dark cycle
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with a regular mouse diet at the University of Louisville School of Medicine animal
facility. Mice were cared according to ARVO guidelines, as approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of Louisville, Louisville,
KY. The experimental protocols were performed following the National Institute of
Health guidelines (NIH Pub. No. 86–23, revised 1985). Genotyping of the mice was
carried out by collecting the tail biopsy. DNA was isolated using the DNeasy Blood and
tissue kit (Qiagen, Germantown, MD). The cross‐breeding yielded Ins2Akita with high and
low glucose levels, as measured by blood glucose meter Ultra Touch 2 (Life Scan, USA).
The high glucose level category consists of mice with blood glucose levels that were
greater than or equal to 300 mg/dL, and the low glucose levels were animals exhibiting
less than or equal to 250 mg/dL. Only mice with high glucose levels used in the
experiments.

Mice were divided into four different groups: (a) WT, (b) WT + JSH-23, (c) Ins2 Akita,
and (d) Ins2Akita + JSH-23. JSH-23 purchased from Sigma (Sigma Aldrich, St. Louis,
MO; CAS# 749886-87-1). A stock solution of JSH-23 was prepared by diluting 25 mg in
1000 microliter (µL) of 200 proofs ethanol (Decon Labs, King of Prussia, PA; CAS# 6417-5) and stored at -70 degrees Celsius. A 100 µL of the stock solution diluted with 4900
µL of 1X sterile phosphate-buffered saline (PBS). The control solution prepared with
4900 mL of 1X PBS and 100 mL of 200 proofs ethanol. Akita and wild type (WT)
C57BL/6J mice strains were treated with or without a specific and selective inhibitor for
the translocation of the NF-κB (i.e. with JSH-23) intraperitoneally (IP) @ 5mg/Kg body
weight on alternate days for a total of 4 weeks. Blood pressure (CODA Instrument),
blood glucose (Ultra Touch 2), body weights (OHAUS, CS-2000 Balance), and
intraocular pressure (iCare, Tonolab) were measured before and after the injections of the
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NF-B inhibitor (Fig. 9).

Measurement of body weight, blood glucose, blood insulin, and glucose tolerance test.
Body weights of all the animals recorded using an electronic weighing balance (OHAUS,
CS-2000). ELISA. Mouse INSULIN ELISA kit (EMINS) from Thermo Fischer Scientific
(Waltham, MA) was used to analyze plasma insulin levels. The test performed according
to manufacture instructions.
Intraperitoneal Glucose Tolerance Test. The glucose tolerance test used to measure the
clearance of an IP injected glucose load from the body and to detect disturbances in
glucose metabolism that linked to diabetes or metabolic syndrome. Glucose (200 mg/ml)
was injected IP (@ 2g per kg body weight after 6 hours of fasting. Blood glucose was
measured (tail vein) at 0, 30, 60, 90, and 120 minutes after the injection using Ultra
Touch 2 [235].

Reagents and Antibodies. Antibodies and chemicals were purchased from trusted sources
such as Sigma-Aldrich, Abcam, Cell Signaling Technology, or Santa Cruz
Biotechnology. Details for the antibodies are; iNOS (ab15323) and NLRP3 (ab214185)
purchased from Abcam (Cambridge, MA, USA). COX-2 (4842S), Total NF-κB p65
(8242S), and p-NF-κB p65 (3033S) purchased from Cell Signaling Technology (Danvers,
MA, USA). ICAM-1 (sc-107) purchased from Santa Cruz Biotechnology (Dallas, TX).
The secondary antibodies also purchased from Santa Cruz Biotechnology, namely rabbit
anti‐mouse (sc‐358914), mouse anti‐rabbit (sc‐2357), and mouse anti‐goat (sc‐2354).
GAPDH (MAB374) was purchased from EMD Millipore (Burlington, MA). All
reagents/antibodies were used for Western Blotting following the manufacturers’
57

recommended protocols.
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Figure 9. Treatment plan. The blood glucose, blood pressure, IOP, and body weight of
the animals were measured before and after treatment with JSH-23. The treatment was
carried on alternate days for four weeks.
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FIGURE 9
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Western Blotting. Protein expression profiles were performed via Western blots analyses.
Retinas were separated from enucleated globes from the euthanized mice, and the retinal
protein lysates were used immediately or snap‐frozen in liquid nitrogen and stored at –
80°C until further use. Protein were extracted via homogenizing in RIPA buffer (Boston
BioProducts, Worcester, MA). These cocktails were added to the RIPA buffer; a cocktail
of 1 mmol/L phenylmethylsulfonyl fluoride (Sigma, Saint Louis, MO), 1% protease
inhibitors cocktail (Sigma). Then the samples were sonicated with the Sonifier 450
(Branson Ultrasonics, Danbury, CT). The homogenates were centrifuged at 15,000
rpm for 15 min at 4°C, and the resultant supernatants were collected and stored at –80°C.
Bradford assay was used to estimate the total protein contents. Per sample, 40 μg of total
protein amount resolved on a 10% SDS‐PAGE and then transferred to polyvinylidene
difluoride (PVDF) membrane. The membranes were incubated with primary antibodies
overnight and then with the secondary antibodies were added the next day for 3 hours
before visualization with ECL Luminata Forte (Millipore, Temecula, CA) via a Bio‐Rad
ChemiDoc system (BioRad Laboratories, Des Plains, IL, USA). Band intensities were
normalized to GAPDH for all the target proteins analyzed, and their respective
quantifications were performed through Image Lab™ Software (Bio‐Rad, Hercules, CA).

Quantitative PCR. RNA was isolated with TRIzol® reagent (Life Technologies,
Carlsbad, CA, USA) based on the instruction of the manufacturer. Nanodrop-1000
(Thermo Scientific, Waltham, Ma) was used to analyze RNA quantification and purity.
Im Prom-II TM Reverse Transcription System (A300, Promega, Madison, WI) was used to
reverse-transcribe the total RNA into cDNA per instructions of the manufacturer.
Quantitative PCR (qPCR) was performed for different transcripts
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(RelA, iNOS, COX-2, ICAM-1, Cx43, Occludin, NLRP3, Casp-1, IL-1). The final
reaction included 10 l of nuclease-free water, 8 l of Bullseye EvaGreen qPCR
Mastermix (BEQPCR-S, MIDSCI, Valley Park, MO), 50 picomoles of forward and
reverse primers, and 1l of cDNA (Table 1). The data were normalized with
housekeeping gene GAPDH.

Statistical Analyses. All values are reported as mean ± SEM. One‐way ANOVA was used
to analyze the difference between the groups, including a Tukey's post hoc analysis for
groups’ comparisons. The tests were performed with p<0.05 and a total number of mice
(n) = 5–20 were subjected toanalysis depending upon particular experiments from each
group. GraphPad Prism (Ver 8.1, GraphPad Software) used during analyses.

Results
Confirmation of Ins2Akita Mutation in the Expanded Mouse Colony and Effect of JSH-23
on Glucose Metabolism. Mice tail DNA samples were analyzed using PCR employing
specific primers to determine the mice genotype. Genotyping revealed the mutated
version of the insulin gene exhibiting two discrete bands: 280 and 140 bp representing the
heterozygous status while wild‐type (WT) mice showed one 140 bp band (Fig. 10A). To
generate mice for the study, Akita female with low blood glucose (LG) were cross-breed
with male Akita mice with high glucose (HG). Cross‐breeding yielded Akita progeny
with HG and LG levels as measured by blood glucose (BG) meter Ultra Touch 2 (Life
Scan, USA). Only Akita mice with a BG level <300 mg/dL were used in this study.
Akita mice have a mean BG level of 596.47 mg/dL, significantly higher than C57BL/6J
BG of 173.47 mg/dL (p<0.0001, n=15 per group). JSH-23 significantly decreased
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Table 1. Nucleotide sequence. Forward and reverse primers gene sequences for each
gene analyzed.
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TABLE 1
Gene

Forward Sequence

Reverse Sequence

Rel A[236]

5’- GCCCAGACCGCAGTATCC

5’- GTCCCGCACTGTCACCTG

iNOS [237]

5’- CAGCTGGGCTGTACAAACCTT

5’- CATTGGAAGTGAAGCGGTTCG

COX-2 [238]

5’- CAGAACCGCATTGCCTCTG

5’- TTGTAACTTCTGGTCCTCATGTCGA

ICAM-1[239]

5’- TTCACACTGAATGCCAGCTC

5’- GTCTGCTGAGACCCCTCTTG

Cx43 [240]

5’- CCAAGGAGTTCCACCACTTTG

5’- CCATGTCTGGGCACCTCTCT

Occludin[241]

5’- AGACCCAAGAGCAGCCAAAG

5’- GGAAGCGATGAAGCAGAAGG

NLRP3 [242]

5’- CTTCTAGCTTCTGCCGTGGTCTCT

5’- CGAAGCAGCATTGATGGGACA

Casp-1[242]

5’-GTACACGTCTTGCCCTCATTATCTG

5’- TTTCACCTCTTTCACCATCTCCAG

IL-1 

5’-CAACCAACAAGTGATATTCTCCATG

5’- GATCCACACTCTCCAGCTGCA

64

Figure 10. Genotyping and Physiological Parameters of Akita, and C57BL/6J Mice.
A. Genotyping of Akita, and C57BL/6J mice. B. Body weight of the Akita, and the
C57BL/6J, Akita mice body weights were significantly lower than the body weights of
the C57BL/6J mice (p<0.0001, n=19 per group). C. The blood glucose level of Akita,
and C57BL/6J mice the blood glucose levels of Akita mice were significantly higher than
C57BL/6J mice (p<0.0001, n=15 per group). JSH-23 significantly decreased blood
glucose levels in Akita mice (p<0.0001). D. Plasma insulin levels of Akita mice were
substantially lower (p<0.0001, n=19 per group). E. Intraperitoneal glucose tolerance test
depicted the inability of the Akita mice to lower their blood glucose levels (p<0.009, n=5
per group).
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Figure 11. Expression of NF-B p65 in the retinae of Akita, and C57BL/6J mice
after treatment with JSH-23. A. Immunoblotting image of total and phosphorylated
NF-B p65. B. The total expression level of NF-B p65 was significantly elevated in
Akita mice (p<0.05, n=7 per group). JSH-23 significantly decreased the total expression
of NF-B p65 in Akita mice (p<0.005). C. The phosphorylated expression level of NFB p65 significantly elevated in Akita mice (p<0.05, n=7 per group). JSH-23 could
significantly decreased the phosphorylated expression level of NF-B p65 (p<0.05). D.
The gene expression of NF-B p65 was significantly elevated in Akita mice (p<0.0001,
n=7). JSH-23 significantly decreased the gene expression of NF-B p65 in Akita mice
(p<0.0002).
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Figure 12. Expression levels of ICAM-1, iNOS, and COX-2 in the retinae of Akita,
and C57BL/6J mice after treatment with JSH-23. A. Immunoblotting image of ICAM1, iNOS, and COX-2. B. The expression level of ICAM-1 was significantly elevated in
Akita mice (p<0.0218, n=6 per group). JSH-23 significantly decreased the expression of
ICAM-1 in Akita mice (p<0.0028). C. The expression level of iNOS was significantly
elevated in Akita mice (p<0.0001, n=6 per group). JSH-23 significantly decreased the
expression of iNOS in Akita mice (p<0.0001). D. The expression level of COX-2 was
significantly elevated in Akita mice (p<0.0001, n=6 per group). JSH-23 significantly
decreased the expression of COX-2 in Akita mice (p<0.0001).
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Figure 13. Gene expression level of ICAM-1, iNOS, and COX-2 in the retinae of
Akita mice, and C57BL/6J treated with JSH-23. A. ICAM-1 gene expression was
elevated in Akita mice (p<0.0003, n=5 per group). JSH-23 decreased the gene expression
in Akita mice (p<0.0001). The iNOS gene expression was elevated in Akita mice
(p<0.0012, n=5 per group). JSH-23 decreased iNOS gene expression levels in Akita mice
(p<0.0031). COX-2 gene expression was increased in Akita mice (p<0.0004, n=5 per
group). JSH-23 reduced the expression of COX-2 in Akita mice (p<0.0001).
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Figure 14. Pyroptosis Marker in the retinae of Akita, and C57BL/6J mice treated
with JSH-23. A. Immunoblotting imaging of NLRP3. B. NLRP3 expression level was
elevated in Akita mice (p<0.018, n=6 per group). JSH-23 decreased NLRP3 expression in
Akita mice (p<0.0003). C. NLRP3 gene expression was increased in Akita mice
(p<0.0025, n=6 per group). JSH-23 decreased the gene expression level of NLRP3 in
Akita mice (p<0.0003). D. Casp-1 gene expression increased in Akita mice (p<0.0001,
n=6 per group). JSH-23 decreased the gene expression of casp-1 (p<0.0001). E. IL-1
gene expression was elevated in Akita mice (p<0.0001, n=6 per group). JSH-23
decreased the gene expression level of IL-1 (p<0.0001).
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Figure 15. Expression of Junctional Molecules in the retinae of Akita, and C57BL/6J
mice treated with JSH-23. A. Immunoblotting image of Cx43, and occludin. B. Cx43
expression was decreased in Akita mice (p<0.0165, n=5 per group). JSH-23 increased the
expression of Cx43 (p<0.0006). C. Occludin expression was decreased in Akita mice
(p<0.0068, n=5 per group). JSH-23 decreased the expression of occludin (p<0.0071). D.
Cx43 gene expression was decreased in Akita mice (p<0.003, n=5 per group). JSH-23
increased the gene expression in Akita (p<0.0237). E. Occludin gene expression was
decreased in Akita mice (p<0.0073, n=5 per group). JSH-23 increased the gene
expression of occludin (p<0.006).
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the mean (456.2 mg/dL, p<0.0001) blood glucose level in Akita mice (Fig. 10C). Akita
mice have a mean body weight of 26.60g, substantially lower than C57BL/6J mice with a
mean of 30.82g (p<0.0001). JSH-23 did not have any effect on the mean body weights of
the Akita mice (Fig. 10B). Akita displayed significantly lower plasma insulin levels
(p<0.0001) (Fig. 10D). As expected, results from IP administered glucose tolerance test
(ipGTT) showed high basal glucose levels in Akita in comparison to C57BL/6J mice.
Furthermore, ipGGT also revealed that the Akita strain was unable to lower its glucose
level (p<0.0090) in their blood (Fig. 10E).

JSH-23 Diminishes Key Inflammatory Molecules in the Diabetic Retinae. Western
blotting and qPCR analyses were used to examine the effects of systemic inhibition of
NF-κB in mice retinae. The total (p< 0.0353) and phosphorylated amounts (p<0.0463) of
expression levels of NF-B p65 were elevated in the retinae of Akita mice. NF-B p65
subunit gene expression (p<0.0001) was also elevated in the retina of Akita mice. JSH-23
decreased the total (p<0.0053) and phosphorylated (p<0.0254) and gene expression
(p<0.0002) levels of NF-B p65 (Fig. 11).
ICAM-1 expression level (p<0.0218) and the gene expression (p<0.0003) were
elevated in the retinae of Akita mice. JSH-23 decreased the expression level (p<0.0028)
and gene expression (p<0.0001) of ICAM-1 in the retinae of Akita mice. The iNOS
expression level (p<0.0001) and gene expression (p<0.0012) were increased in the retinae
of Akita mice. JSH-23 decreased the expression (p<0.0001) and gene expression
(p<0.0031) levels of iNOS in the retinae of Akita mice. COX-2 expression (p<0.0001)
and gene expression levels (p<0.0004) were increased in the retinae of Akita mice. JSH23 decreased expression level
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(p<0.0001) and gene expression levels (p<0.0001) of COX-2 in the retinae of Akita mice
(Fig. 12 & 13).

JSH-23 Decreases Expression of Pyroptosis Markers in the Diabetic Retinae. NLRP3
expression (p<0.0180) and gene expression levels (p<0.0025) were increased in the
retinae of Akita mice. JSH-23 decreased expression (p<0.0003) and gene expression
levels (p<0.0003) of NLRP3 in the retinae of Akita mice. The gene expressions levels of
casp-1 (p<0.0001) and IL-1 (p<0.0001) were increased in the retinae of Akita mice.
JSH-23 decreased gene expression levels of casp-1 (p<0.0001) and IL-1 (p<0.0001) in
the retinae of Akita mice (Fig. 14).

JSH-23 Augments Integrity of the Tight and Gap Junctions Proteins in the Diabetic
Retinae. Cx43 expression (p<0.0165) and gene expression levels (p<0.0003) were
elevated in the retinae of Akita mice. JSH-23 increased expression (p<0.0006) and gene
expression levels (p<0.0237) in the retinae of Akita mice. Occludin expression
(p<0.0068) and gene expression levels (p<0.0073) in the retinae of Akita mice were also
modulated as can be seen that JSH-23 increased the expression (p<0.0071) and gene
expression levels (p<0.0060) of occludin in the retinae of Akita mice (Fig. 15).

Discussion
There are several mouse models of T1D induced DR that vary in etiology,
severity, mode of inheritance, progression, and overall disease pathology. Akita strain of
mouse becomes diabetic due to a mutation in the insulin 2 (Ins2) gene that results in
improper folding of the insulin protein, thus causing a toxic injury to β-cells of the
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pancreas. This structural alteration in the insulin molecule impairs insulin secretion, OS,
cell death, and an impairs glucose-stimulated insulin release. This also produces toxic
byproducts, leading to a severe inflammatory changes in the diabetic retinae causing the
retinovascular permeability, and leukostasis [144, 216-218, 243]. NF-κB is the first
responder to harmful stimuli for the cells. Known inducers of NF-κB are ROS, IL-1β,
bacterial LPS, and ionizing radiation mediated DNA damage [244-248]. NF-κB is a
family of transcription factors, RelA (p65), that hetero/homodimerize, translocate to the
nucleus to augment NF-B directed genes’ expression, particularly the inflammatory
mediators [121].
Inflammatory mediators such as iNOS, COX-2, and ICAM-1 are elevated in the
retinae of DR, associated with iBRB breakdown, thus increasing the retinal vascular
permeability. Increased leukostasis mediated by ICAM-1 is associated with an increase in
the vascular permeability [234]. HgA induces leukostasis in retinal vessels in rodents that
leads to endothelial apoptosis [249-251]. Leukostasis impairs vision via two proposed
mechanisms: (a) iBRB breakdown due to cellular apoptosis in the endothelium and (b)
endothelial apoptosis that leads to avascular capillaries; thus, nonperfusion or
hypoperfusion which in turn results into neovascularization [251]. NF- plays an
essential role in inflammation and leukostasis via ICAM-1.
Inflammation of the retinal vasculature was significantly diminished as
demonstrated by expression analyses of the critical inflammatory mediators such as
ICAM-1, COX-2, and iNOS in the retinae of Akita mice. Also, the total NF-B p65, and
pNF-B p65 activities were significantly reduced, indicating a clear readout of the
specific inhibition of the critical transcription factor that is responsible for mounting
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immune response in the diabetic retinae. In diabetes, leukocyte adhesion to retinal
endothelium is the primary mechanism of leukostasis. This adhesion is mediated by the
upregulation of ICAM-1 due to NF-B activation, which increases ICAM-1 expression.
Increased leukostasis is associated with enhanced vascular permeability [166-168].
Furthermore, inhibition of ICAM-1 has shown to reduce the leakage and leukocytes
adhesion along with a decrease in leukocytes adherence in diabetic rats [169]. Prominent
inflammatory mediators like iNOS, COX-2, and ICAM-1 were elevated in the diabetic
retinas, as shown in this study. These molecules are associated with iBRB breakdown
leading to an increase in the retinal vascular permeability during diabetes because of the
chronic inflammation that potentially contributes to iBRB breakdown. It was reported
that inhibition of NF-B activation by calcium dobesilate prevented degradation of
occludin in part by decreasing the expression of ICAM-1 [58].
Similarly, the HgA induced downregulation of Cx43 severely affected the GJIC
in the blood vessels and that has again been shown to contribute to iBRB integrity during
DR pathogenesis [252]. Low expression of Cx43 was concurrently associated with other
companion junctional proteins such as occludin and ZO-1 that were also found to be
downregulated [195]. Therefore, we analyzed retinal cell lysates for occludin, and Cx43,
employing Western blotting and qPCR assays. Their expression levels in JSH-23-treated
Akita mice were increased significantly. JSH-23 was shown to be a protective agent by
attenuating the loss of Cx43 during the hypoxic environments [253]. Furthermore, others
have shown that specific inhibition of NF-κB by JSH-23 attenuated the pathological
sprouting of the lymphatic vessels [254]. NF-B activation also activated the assembly of
the NLRP3 inflammasome. NLRP3 has been shown to be active during inflammation,
and activation of inflammasome in the retinae [242, 255, 256].
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Pyroptosis, and inflammatory cell death both activate via the assembly of the
NLRP3 inflammasome that further enables casp-1, which then cleaves the IL-1. Retinal
vascular cell death during HgA causes the breakdown of iBRB. HgA induced activation
of casp-1, and IL-1 has been reported in causing Müller cell death [193]. This study
showed an increase in NLRP3 expression level and the gene expression of casp-1, and
IL-1 in the retinae of Akita mice. JSH-23 significantly decreased NLRP3 expression
levels and the gene expression of both casp-1 and IL-1 in the retinae of Akita mice.
The incidence of T1D is rising, and glycemic variability is common among
young children these days. This has long-term implications for health and well-being for
the diabetics. Research has identified several potential options to cure T1D, but none of
them have shown any concrete outcome till today. Thus, targeted interventions are
needed to reduce the risk of long-term T1D-related complications, and improve the
immediate quality of life in patients. The NF-κB molecule is a critical player in the
inflammatory process; thus, strategies inhibiting NF-κB has potential therapeutic
applications in the fight against diabetes. The result of this study showed that the
sustained long-term inhibition of NF-κB activity could significantly diminish the
degradation of cell-junctional molecules in the retinae of Akita mice.

Conclusion: Inflammatory mediators such as ICAM-1, INOS, and COX-2 expression
were elevated in the retinae of Akita mice. That upregulation of inflammatory mediators
was associated with the activation of NF-B p65. Elevated levels of inflammatory
mediators are linked with the degradation of junctional molecules, thus impairing the
iBRB. JSH-23 decreased NF-B p65 expression levels in the retinae of Akita mice along
with inflammatory mediators (ICAM1, INOS, and COX-2) expression in the retinae of
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Akita mice. JSH-23 treatment reduced NLRP3 and other pyroptosis mediators (e.g. casp1, and IL-1). Inhibition of NF-B p65 also upregulated the expression of Cx43, and
occludin in the retinae of Akita mice. Inhibition of NF-B p65 also decreases blood
glucose level. That decrease could be due to an increase in insulin sensitivity in the Akita
mice.
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CHAPTER IV
EFFECT OF JSH-23 ON VISION IN AKITA MICE

Introduction
T1D predisposes patients to long-term complications like kidney failure,
neuropathy, and blindness. Lately, the incidence of T1D is rising, and glycemic
variability is becoming more common in the younger population. Although T1D is
considered an autoimmune disease, it is not clear what exactly causes the immune system
to attack the beta cells in the pancreas. Up to 90 percent of T1D patients can develop
retinopathy post-diagnosis; as a result, it is becoming a severe medical problem globally.
DR is the leading cause of blindness in the working-age adults [250]. Unfortunately,
there is no cure for DR.
HgA causes endothelial damage and capillary nonperfusion, ultimately leading to
retinal hypoxia. This prompts the growth of abnormal blood vessels in the eye. Early
detection and timely intervention can reduce the risk, but vision loss is irreversible.
Research in the past has identified several options to treat T1D but not all benefit the
majority of patients. Thus, more study needed to address the vascular pathology that
occurs in the retinae.
HgA is known to cause sustained ROS generation, ATP depletion, ER stress,
and, finally, inflammation as a complication of DR pathogenesis. This eventually leads to
microvascular damage, basement membrane thickening, iBRB breakdown, capillary cell
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death, acellular capillary, neovascularization, and sometimes the detachment of the retina
itself.
Inflammatory mediators such as iNOS, COX-2, and ICAM-1 are elevated in the
retinae of DR, and are associated with iBRB breakdown, thus increasing the retinal
vascular permeability. Increased leukostasis is related to an increase in vascular
permeability too [234]. HgA induces leukocytes adhesion in rodents retinal vessels that
leads to endothelial apoptosis [249-251]. NF- plays an essential role in inflammation,
and leukostasis via ICAM-1.
iBRB breakdown is strongly associated with the release of proinflammatory
factors such as iNOS, and elevated levels of inflammatory markers that play a definitive
role in raising IOP. Additionally, IOP elevation linked with the upregulation of the
hypoxia-inducible factor-1 alpha (HIP-1α), interleukins, and VEGF [257]. Inflammation
contributes to BRB breakdown and thus increases the intraocular pressure (IOP).
In this study, we decided to inhibit NF-κB, the first responder during the
inflammation, employing a T1D mouse model and demonstrate that specific targeting of
the NF- activity could help prevent chronic inflammation that is responsible for the
degenerative changes in the retinae. Our findings highlight the significance of targeted
intervention in reducing the long-term diabetic complications and thus improving the
underlying constant inflammatory milieu that is propagated by chronic metabolic
dysfunction in the diabetic patients.

Methods
Systemic Blood Pressure (BP) and Intraocular Pressure. The systemic blood pressure
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was measured with CODA noninvasive blood pressure instrument (Kent Scientific,
Torrington, CT). The IOP was recorded by a Tonometer (iCare, Tonolab). Both pressure
were measured before and after the JSH-23 treatment in mice [258].

Fluorescein Angiography. Mice injected by IP with 100 µl of AK-FLUOR® (NDC
17478-253-10, Akorn, Inc, Lake Forest, IL) after induction of anesthesia with 300 cc of
2x tribromoethanol (TBE). The fundus was visualized by Micron IV microscope
(Phoenix Technology Group, Pleasonton, CA). Images were analyzed via ImageJ for the
presence of fluorescence outside of the retinal capillaries [259] .

In vivo Electroretinography (ERG), and Optical Coherence Tomography (OCT).
Electroretinograms (ERGs) were performed on C57BL/6J and Akita age-matched mice.
Briefly, mice were dark-adapted overnight, and anesthetized by IP using TBE. After
pupils were dilated, full-field scotopic ERGs were recorded using the Tucker–Davis
System Workstation (Tucker–Davis Technologies, Alachua, FL) for the real-time
visualization of the averaged a- and b-waves. The BioSigRZ system was used for the
quantification, and further analysis. OCT was performed to measure the anatomical
differences in the retinal layers before and after treatment with JSH-23, employing the
Image-Guided OCT2 equipment (Phoenix Technology Group, Pleasonton, CA)

Light-dark Box Chamber Test. The animals were subjected individually one by one for the
light-dark box test into the light chamber with the light close. Then, PACS Shuttle Box
Version 3.40 was set up with Experiment Mode as “Passive Avoidance”, UCS Grid
Intensity (Amperes): 0, Exploration duration: 30
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seconds, Maximal Trial Duration: 5 minutes, CS Light Intensity: 10 volts, UCS Grid
Duration: 2 seconds. After 30 seconds of exploration, the light flickered on. Then the time
it took the mice to transfer from the light chamber to the dark was measured [260].

Statistical Analyses. All the values are reported as mean ± SEM. One‐way ANOVA was
used to analyze the difference between the groups, including a Tukey's post hoc analysis
for groups’ comparisons. The tests were performed with p<0.05 and a total number of
mice (n) = 5–20 were subjected to experimentations from each group. GraphPad Prism
(Ver 8, GraphPad Software) was used during the subsequent analyses.

Results
Monitoring of Systemic Blood Pressure and Intraocular Pressure. We next evaluated
systemic and IOP before and after JSH-23 treatment. It is known that JSH-23 increases
blood pressure in hypertriglyceridemic (HTG) rats [261], therefore; we sought to
determine whether JSH-23 did any alteration to the mice systemic blood pressure. To find
that out, we subjected treated and untreated mice to a noninvasive tail-cuff method for
recording blood pressure. None of the mice acquired showed any statistically significant
change in their blood pressures. For example, the mean blood pressure in Akita mice was
117.15 mmHg, and for C57BL/6J strain it was 90.17 mmHg. JSH-23 did not have any
effect on the treated Akita mice with a mean of 102.7 mmHg (Fig. 16A). The mean IOP
of the Akita mice was 25.33 mmHg vs. 14.55 mmHg for C57BL/6J (p<0.0001, n=12 per
group). However, JSH-23 did decrease the IOP in Akita mice, 16.02 mmHg (p<0.0001)
(Fig 16B).
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Figure 16. Systemic Blood Pressure and Intraocular Pressure (IOP) in Akita and
C57BL/6J mice strains. A. JSH-23 does not affect the systemic blood pressure (n= 8 per
group). B. IOP was elevated in Akita mice (p<0.0001, n=12 per group) and JSH-23
treatment decreased IOP in the Akita mice (p<0.0001).
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FIGURE 16
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Figure 17. Fundus imaging of Akita, and C57BL/6J treated with JSH-23. The retinae
of Akita mice depicted derailment in their vasculature network and the treatment with
JSH-23 could repair these vasculature derailments in the affected retinae.
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FIGURE 17
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Figure 18. Fluorescence Angiography in Akita, and C57BL/6J strains treated with
JSH-23. The retinae vasculature of Akita mice showed an increased vascular
permeability (p<0.0001, n=6 per group). And treatment with JSH-23 decreased the
vascular permeability in Akita mice strain (p<0.0001).
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FIGURE 18
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Figure 19: Optical Coherence Tomography in Akita, and C57BL/6J treated with
JSH-23. The retinal layer’s thickness decreased in Akita mice (p<0.0001, n=5 per
group) and the treatment with JSH-23 prevented the retinal thickening (p<0.0001).
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FIGURE 19
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Figure 20: Electroretinogram of Akita, and C57BL/6J mice strains treated with
JSH-23. A. Electroretinograms of C57BL/6J, and Akita mice treated and non-treated
with JSH23. B. Electroretinograms superimposed on top of each other on excel
spreadsheet C. Amplitude of A-wave in the retinae of Akita was found to be decreased
(p<0.0001, n=6 per group) and the treatment with JSH-23 prevented this decrease in the
A-wave amplitude in Akita (p<0.0001). D. The amplitude of B-wave in Akita mice was
also decreased (p<0.0001, n=6 per group) aand treatment with JSH-23 could prevent this
decrease in B-wave amplitude in the Akita mice (p<0.0001).
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FIGURE 20
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Figure 21: The light-dark chamber movement analysis of Akita and C57BL/6J mice treated
with JSH-23. A. Assessment of vision-guided behavior employing a light-dark chamber, it took
Akita mice significantly longer to move from the dark to the light chamber (p<0.0001, n=8 per group)
relative to C57BL/J6. Akita treated with NF-kB inhibitor demonstrated significantly decrease time

taken by them to move from light chamber to the dark chamber (p<0.0477, n=10 per group).
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FIGURE 21
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Assessment of Retinal Fundus. The retinal fundus images of Akita mice depicted the
degeneration of the retinal blood vessels along with yellow spots that appeared to be
cellular debris like structure and the treatment with JSH-23 seemed to prevent the
degeneration of these inflamed retinal blood vessels in Akita mice post treatment (Fig.
17).

Assessment of Retinal Vasculature by Fluorescein Angiography (FA) and Fundoscopy.
Retinal complications such as vascular damage is consistent with T1D. We know that
HgA-led inflammation causes retinal vascular leakage, and microaneurysm formation.
We studied the anti-inflammatory effects of JSH-23 on the retinal vasculature employing
in vivo FA [218]. The results showed diminished retinal permeability in the JSH-23
treated mice (p<0.0001, n=6 per group) (Fig. 18). Interestingly, a decrease in perfusion
time (time is taken by fluorescein isothiocyanate; FITC dye to perfuse the retinal
vasculature completely) in Akita mice of about 2 minutes was observed after an IP
injection of the dye. There was also an increase in microaneurysm formation in the Akita
mice as expected (Fig. 18).

In vivo Electroretinography and Optical Coherence Tomography (OCT). Functional
changes in the retinae was evaluated by full-field scotopic electroretinograms (ERGs) on
C57BL/6J, and Akita mice employing the BioSigRZ system. Akita mice demonstrated
widened and truncated A and B waves in contrast to the sharp A, and B waves in
C57BL/6J mice strain. ERGs of treated, and non-treated of Akita and C57BL/6J showed
in Fig 20A and Fig.20B. Also, the A-wave was significantly reduced in Akita mice
compared to WT (p<0.0001 n=6 per group). The average amplitude for Akita mice was
32.88 V vs.
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66.18 V of thw C57BL/6J mice. JSH-23 did increase the magnitude of the A-wave in
Akita mice, as shown by mean value of 61.75 mV (p<0.0001) (Fig. 20C). On the other
hand, the B-wave amplitude showed a significant difference between Akita, and
C57BL/6J strains e.g. 103.78 V vs. 207.53 V (p<0.0001, n=6 per group). JSH-23
treatment increased the amplitude, and mean of 150.2 mmHg (p<0.0001) (Fig. 20D).
Retinal structural integrity was evaluated employing real-time, image-guided OCT in
Akita strain that displayed hyporeflective retinal lucency (blue arrows) along with
abnormal thickening of the membrana limitans interna, inner nervous stratum opticum,
and GCL. The retinal thickness layer was reduced in the Akita strain with a mean of
128.58 m, and 254.25 M C57BL/6J mice (p<0.0001, n=5 per group). JSH-23
prevented degradation of the retinal thickness layer in Akita mice, as reflected by the
mean value of 254.25 (p<0.0001) (Fig. 19C).

Evaluation of Vision Guided Behavior in JSH-23 Treated Mice
Finally, the mice were evaluated for their vision-guided behavior employing a light-dark
chamber analysis. It took Akita mice significantly longer to move from the dark to the
light chamber (p<0.0001, n=8 per group) relative to C57BL/J6. The results revealed that
Akita mice treated with JSH-23 demonstrated significantly decreased time taken by them
to move from the light chamber to the dark chamber post treatment (p<0.0477, n=8 per
group).

Discussion
We hypothesized that activation of NF-κB, and its nuclear translocation could be
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separated from other biological processes, thus giving us an opportunity to test the
potential strategy of targeting specifically NF-κB activity for a longer duration on a
sustained basis, and study its beneficial effect(s) in a well-characterized T1D mouse
model. The model exhibits degenerative changes in the retinal architecture, including its
blood vessels leading to the development of symptoms mimicking DR pathology [262].
By this account, treatment with inflammatory inhibitor such as JSH-23 should in
principle, prevent the development of DR phenotype. To test this hypothesis, C57BL/6J
and Ins2Akita (Akita) strain of mice were treated with JSH-23 or without for a total period
of four weeks continuously. Several disease indicators, such as IOP, blood pressure,
visual function, were evaluated systematically one by one. For assessing the structural,
and functional aspects of the retinae methods such as FA, OCT, and ERG with or without
JSH-23 treatment were employed. Our findings revealed that JSH-23 significantly
decreased the retinal vasculopathy in the diabetic retinae, and retinal structure was
successfully protected as evidenced by OCT, and a concurrent decrease in
the vascular leakage as shown by fundus photography and FA analyses. Further, the data
indicated that visual function were affected in the Akita mouse and is consistent with
previously described results [218]. Similar changes in the mouse models of hypertension,
and retinal neovascularization depicted severe capillary non-perfusion, vessel
constriction, beading, neovascularization, fibrosis, and edema that have been reported in
the literature [263]. These changes are associated with inflammation and activation of
NF-B. Our findings indicate that mitigation of DR severity and its pathology are
possible via timely inhibition of inflammation on a sustained basis using a selective
inhibitor of inflammation.
Chronic inflammation during diabetes is associated with iBRB breakdown that
leads to an increased retinal vascular permeability, and thus elevate IOP, thereby
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decreasing vascular permeability. In our study the IOP also improved, as did visual
function which were revealed by the ERG analyses when inflammation was successfully
arrested. Notably, the inflammatory response to injury has also been shown to be
effectively attenuated by the JSH-23 treatment in another model system, as well [264]. In
a nutshell, this study advances our understanding of the role of inflammation in DR, and
sheds important light on one of the approaches to further reduce the inflammatory insults
in a privileged organ-like the eye. However, additional studies are needed on how best to
deliver the JSH-23 therapeutically in a clinical setting or its more potent versions directly
into the eye in a longer-acting fashion. The results did show diminished retinal
permeability in the JSH-23 treated mice, again confirming that inhibition of inflammation
via NF-κB inhibition could help protect the retinal vasculature in the diseased eyes.
Therefore, the results from the present work indicate that mitigation of DR severity, in
fact, is possible via inhibition of inflammation using a selective inhibitor.

Conclusions. Treatment with JSH-23 successfully decreased IOP in Akita mouse strain
without change in systemic BP noticed. One of the significant findings that came out of
this work is that the inhibition of inflammation perhaps helped improve the vision in
Akita mice thus indicating that controlling inflammation could potentially decrease
retinal inflammatory insults, and therefore improve the structural, as well as, functional
attributes of the diabetic retinae in a chronic disease such as diabetes.
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CHAPTER V
CONCLUDING DISCUSSION
T1D or insulin-dependent diabetes is a chronic illness that is usually diagnosed
during childhood [220-222]. Clinically, diabetes management has proven challenging for
a variety of reasons including physiological factors such as increased insulin sensitivity,
especially in children [223]. T1D leads to the degeneration of microvascular network. DR
costs the US government 1/2 a billion dollar in medical cost every year [265]. According
to the National Eye Institutes (NEI), in 2010 there were approximately 7.7 million
individuals living with DR, and that number is projected to double by 2050. Although
more Caucasians are affected by the disease, it is more common in African-Americans
and Hispanics communities [266]. DR affects both type I and type II DM patients,
however DR is twice more common in T1D [225].
DR is the leading microvascular damage in Diabetes. It is defined by leakage of
the blood and other body fluids into the retinae from nearby microvessels followed by
abnormal angiogenesis, increase in permeability, micro aneurysms, loss of pericytes, and
thickening of the basement membrane [226]. DR starts as NPDR, gradually progresses to
DME and or PDR [224]. NPDR is characterized by the presence of hemorrhage,
microaneurysms, abnormality in the retinal microvessels, and the cotton wool spots
(fluffy white patches in the retina). On the other hand, PDR is characterized as an
abnormal growth of blood vessels in the retina [267]. Untreated DR could develop into
DME (fluid accumulation into the macula) or PDR (meovascularization). DME not
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PDR is more prevalent in type II diabetes [268]. Other complications of DR include
retinal detachment. The development of vessels’ growth into the area that drains fluid
from the eye raises IOP to the point that can damage the optic nerve. If left untreated,
PDR causes severe vision loss or even blindness.
Treatment of DR depends on the stage of the disease itself since the goal remains
to slow or stop further disease progression. Many times, laser (photocoagulation) is used
to create burns in the retina to seal the leaks in order to avoid further leakage. Injections
of drugs (anti-vascular endothelial growth factor) in the eye are aimed at stopping the
vascular leakage and new vessel formation. These approaches, along with tight bloodglucose control and dietary measures, may help slow down disease progression in some
people [225, 226]. Current interventions do not adequately address the “retino-vascular”
signature pathology that underlies the initiation, progression, and maintenance of the DR
phenotype. Furthermore, they fail to restore vision in the majority of patients. The
etiology of DR is not fully understood despite an abundance of literature describing the
impact of the polyol flux, hexosamine pathways, AGEs, and OS. However, recently, DR
is regarded as a stand-alone inflammatory disease due to the presence of various
inflammatory mediators that have been repeatedly found in the vitreous and retinas of
both diabetic animals and humans [227]. Inflammation is a response of the immune
system after an injury had occurred or to a foreign entity. The resolution of inflammation
involves cytokines, which upregulate pro-inflammatory proteins [269]. There is a
consistent presence of a chronic inflammatory environment in the diabetics individuals,
which could be mediated by dysregulation of the master regulator i.e. NF-.
Interestingly, a substantial increase in the expression of inflammatory
markers/molecules is directly associated with NF-κB [120], a dynamic transcription
factor that orchestrates complex biological processes, including the inflammatory
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response itself [228]. Owing to its upstream role in cell-signaling, NF-κB is considered as
a central component in the inflammatory response [121, 209, 229, 230]. Dysregulations
of NF- induces overexpression of inflammatory mediators (iNOS, ICAM-1, COX-2)
in the retinas of diabetic animal models and patients [231]. It induces activation of
pyroptosis process (NLRP3, IL-1) [194]. This sustained inflammation could easily lead
to degradation of the iBRB in many susceptible individuals leading to a substantial
decrease in the expression of junctional molecules such as Cx43, and occludin [233].
Furthermore, iBRB impairments also contributes to fluid accumulation in the retina
[232].
There is an increase in inflammatory mediators (NF- p65, COX-2, INOS, and
ICAM-1) in the retina of T1D mice. These mediators are associated with decreasing the
expression of junctional molecules (occludin, and Cx43) leading to iBRB impairment,
increased retinal vascular permeability, and increase in the ocular pressure. The objective
of this study was to investigate whether treatment with JSH-23 mitigates this vision loss
and retinal vascular permeability, thus potentially preventing the development of DR. We
therefore hypothesized that pre-empting inflammation by systemically inhibiting NK-κB
activity with, JSH-23 could mitigate microvascular alterations in the diabetic retinae.
Findings from this study suggest that decreasing the inflammation alone could
protect the diabetic retinae and its vascular network highlighting the fact that regulating
NK-κB may have broad implications in treating chronic inflammatory diseases, including
diabetes and its devastating complications. This study showed a decrease in the blood
glucose of Akita mice after treatment with JSH-23. This decreased in blood glucose level
could be due to increase in insulin sensitivity, byproduct of suppressing inflammation.
JSH-23 decreased the inflammatory mediators (NF-B p65, ICAM-1, iNOS, COX-2) in
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the retinae of Akita mice. It also reduced pyroptosis markers (NLRP3, Casp-1, and IL1) in the retinae of Akita mice. More importantly, JSH-23 also reduced the degradation
of junctional molecules in the retina of Akita mice (occludin, and Cx43). Not only it also
decreased retinal vascular permeability, IOP, in Akita mice but also increased A-wave
and B-wave in Akita mice.
In this study we conclude that during T1D, vision loss is due to retinal vascular
leakage by an increase in inflammatory mediators (NF-B p65, COX-2, INOS, and
ICAM-1), which leads to an increase in retinal vascular permeability, IOP, and the
vision-loss. Treatment with an inflammatory inhibitor (JSH-23) most likely helped
improve vision in Akita as scored via the vision-guided behavioral test.
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Figure 22. Summary. Inhibitor of inflammation (employing the JSH-23) improved
visual function by decreasing the retinal vascular permeability, intraocular pressure, and
retinal inflammation in the T1D Akita mouse model successfully.
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FIGURE 22
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Future Directions
The resident immune cells of the retina are called microglia. They help stabilized
or maintain the homeostasis of the retinal environment. They reside in multiple cell layers
include the IPL, OPL, and the GCL [59]. Microglia exists physiologically into two states:
activated or surveying. It contains receptors for many different neuromodulators or
neurotransmitters such as glutamate, dopamine, bradykinin, and norepinephrine.
Microglia also secretes many substances in responses to injury, inflammation, or
constitutively; NO, ROS, cytokines, and chemokines [59].
Microglial activation is due to extracellular signals, including cell death,
neurodegeneration, nucleic acids, which are recognized via TLRs, which then activate the
pro-inflammatory pathway of NF-B, followed by upregulation of inflammatory
mediators [270]. Microglia are enabled in DR, although the mechanism is still at large.
Some studies in diabetic rats showed that HgA does not change the density of microglia,
but more of them are activated. In human DR patients, the number of microglia
significantly increases, and they migrate towards injured areas such as micro-aneurysms.
Thus, it is still yet to be clear whether microglia in DR in part are protective [270]. Upon
activation, microglia function in presentation of antigen, producing inflammatory
markers, and phagocytoses. Active microglia could also become self-destructive via
inducing the death of retinal cells [271].
HgA activates microglia via increased ROS, which then enables NF-B. NF-B
increases the expression of its pro-inflammatory genes, including IL-1, and ICAM-1
[270]. Hui-yang Zeng et al. reported microglia were activated around the retinal vessels
in the retina of diabetic patients. Activated microglia released IL-1 and other
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proinflammatory mediators, which further impaired the retinal vasculature [272], mainly
via activation of NF-B [273]. In STZ induced rats, Xiaofei Chen et al. found to be a
redistribution of microglia cells in the retinal layers, with the GCL and the NFL depicting
an increase in the microglia populations. In contrast, the IPL has the opposite effect,
which induced retinal thickening [274]. Anti-inflammatory agents, minocycline, was
shown to prevent retinal neuronal cell death in STZ-induced rats by inhibiting the
activation and proliferation of microglial cells [275].
Literature reported on JSH-23 effect focused on immune cells (Macrophages
RAW 264.7). JSH-23 effect on microglial activation in the retinae would be critical to
study the impact on JSH-23 on retinal inflammation. Interestingly, there is no study on
the effect of JSH-23 directly on retinal ECs or pericytes.
They are other factors that this study did not take into account that could also
affect the increase in IOP including the thickness of the cornea and drainage of aqueous
humor.
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